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CRISPR vs. Anti-CRISPR: 
 How bacterial viruses fight CRISPR-Cas immunity 
Adair L. Borges 
 
Abstract 
Bacteria and the viruses that infect them (bacteriophages/phages) are locked in an 
ancient evolutionary arms race. Bacteria use CRISPR-Cas systems as a form of anti-
phage immunity and phages encode “anti-CRISPR” proteins that antagonize CRISPR-
Cas function. Anti-CRISPRs are high-affinity CRISPR-Cas inhibitors, but face a great 
challenge in rapidly neutralizing all the CRISPR-Cas complexes in the cell upon phage 
infection. I show that CRISPR defeats phages with anti-CRISPRs in >90% of infection 
events, and rare successes occur only when multiple phages cooperate to infect the 
same cell. Failed infections “immunosuppress” the bacterium by the production of anti-
CRISPRs prior to phage destruction, increasing chances of survival for other co-infecting 
phages. This is the first description of altruism in viruses. This cooperative strategy for 
CRISPR-Cas neutralization is completely dependent on phage multiplicity of infection: if 
the concentration of phage is too low for coinfections to occur at an appreciable rate, the 
phage population will go extinct. While this strategy may be suitable for some classes of 
mobile elements, others may be unable to obtain cooperation thresholds, necessitating 
enzymatic or hyper-potent inhibitors. In searching for new mechanisms of CRISPR-Cas 
neutralization, we have now discovered anti-CRISPRs that function 
substoichiometrically, one of which has been shown to be a multi-turnover enzyme. 
Furthermore, I show that some phages have hijacked a transcriptional repressor of 
CRISPR-Cas immunity, and deploy it to limit CRIPSR-Cas biogenesis. The 
CRISPR/anti-CRIPSR arms race is a hotbed for evolutionary innovation, and is a source 
of novel and inventive mechanisms of immune neutralization. 
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Chapter 1: Introduction 
 
The genetic diversity of microbes ensures their widespread colonization of the planet. In 
addition to surviving in wide-ranging hostile niches, such as the human body and the depths of 
the ocean, microbes face a constant onslaught from viruses 1. Bacteriophages (phages) are 
bacterial viruses that have earned the reputation of being the most abundant biological entities 
on the planet, with estimates of ~1031 particles on earth 2. Phages are intrinsically specific for 
the bacterial host that they infect, typically being restricted to a single bacterial species and 
even a subset of strains within that species. This specificity has enabled the careful dissection 
of the molecular determinants of phage-host interactions in many model bacterial systems, 
leading to an array of fundamental biological discoveries and ground breaking biotechnologies.  
 
Anti-phage defence  
Along with the widespread presence of viruses on the planet, anti-viral immune pathways are 
ubiquitous across the tree of life. Bacteria achieve resistance to viral infection through diverse 
mechanisms that can be broadly classified into those that act before phage genome injection 
and those that manifest after the phage nucleic acid is in the cell. Prior to phage injection, 
receptors on the cell surface are required for successful for phage adsorption to the cell surface. 
These receptors can be absent, mutated, or masked through specific modifications as an anti-
phage mechanism 3. Additionally, the poorly understood process of phage genome injection can 
be inhibited by proteins localizing to the cytoplasmic membrane or periplasm 4-6. Remarkably, 
many of these anti-phage mechanisms are encoded by integrated phages (prophages) and 
operate through their host as a phage superinfection exclusion mechanism. 
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Once inside the cell, phages that are entering the lytic cycle hijack host processes to convert the 
cell into a viral factory. Before phage replication proceeds to completion, the phage nucleic acid 
(often DNA) may be degraded by bacterial immune systems that target foreign DNA, such as 
restriction enzymes or CRISPR-Cas nucleases. Many of these anti-phage mechanisms have 
been described in detail in excellent reviews on the subject (See 7,8). Other intracellular immune 
systems such as bacteriophage exclusion (BREX) in Bacillus subtilis 9 and phage inducible 
chromosomal island-like elements (PLE) in Vibrio cholerae 10 have recently been discovered 
although their mechanisms of action remain obscure.  
 
Despite the numerous powerful systems that bacteria employ to block phage entry and 
replication, the abundance of phages on the planet shows that these mechanisms have not 
driven phages to extinction. This can be explained, in part, by a plethora of phage-encoded 
mechanisms that inhibit these bacterial defences. Phages can degrade restrictive outer 
membrane modifications, modify tail proteins to utilize alternate receptors, modify their DNA to 
avoid restriction endonucleases, and encode protein inhibitors of various bacterial processes 11. 
Here, we discuss the mechanisms by which phages evade CRISPR-Cas function. 
 
CRISPR-Cas Systems 
Clustered regularly interspaced short palindromic repeats and CRISPR associated genes 
(CRISPR-Cas) comprise a bacterial adaptive immune system that utilizes RNA-guided 
nucleases to cleave foreign nucleic acids. By acquiring small fragments of DNA from a foreign 
element during an initial exposure, the CRISPR array forms a chronological record of past 
genomic transgressors 12-14. The repetitive elements in the CRISPR array provide semi-
palindromic functional elements for both the construction of the CRISPR array and the process 
of interfering with foreign DNA, while the ‘spacer’ elements between the repeats specify the 
	3 
sequence of the target. In fact, the first hints that CRISPR-Cas might comprise an adaptive 
immune system against phages was the identification of spacer sequences that are identical to 
phage genomes 15-17. To function, the CRISPR array is transcribed and processed to generate 
mature CRISPR RNAs (crRNAs) which often possess repeat derived regions at the 5’- and 3’-
ends, with the spacer-encoded sequence in the middle 18,19. This crRNA is assembled with 1-6 
Cas proteins, depending on the type of system and this complex will surveil the cell 20. Upon 
recognition of invading complementary nucleic acid, nuclease activity of at least one enzyme is 
activated and mediates the destruction of that target 21-24. There are currently six distinct 
CRISPR-Cas types, which possess completely distinct sets of proteins that enable function. The 
details of the CRISPR-Cas types and mechanisms of action have been the subject of excellent 
reviews (see 25,26). Here, we will focus on the first two systems for which anti-CRISPRs were 
discovered, Type I (Cas3) and II (Cas9).  
 
Type I CRISPR-Cas systems utilize an RNA-guided protein complex consisting of 3-5 proteins 
that process and guide the crRNA to a complementary target and signal for the recruitment of 
the trans-acting nuclease known as Cas3 18,27,28. Type I CRISPR-Cas systems are further 
categorized into multiple subtypes with distinct RNA-guided protein complexes (I-A through I-F), 
with all utilizing the Cas3 signature protein for DNA degradation 20. In contrast, Type II systems 
possess a single effector protein, Cas9. Cas9 participates in spacer acquisition, crRNA 
processing (together with a trans-encoded small RNA tracrRNA and RNAse III), target 
identification, and cleavage 19,29-32. Type II CRISPR-Cas systems are also broken down into 
three subtypes (II-A through II-C), possessing distinct Cas9 homologs. Due to a reliance on a 
single protein for function, Cas9 homologs derived from different subtypes and species have 
been utilized for numerous far-reaching gene editing applications in recent years 33. In common 
between the type I and II CRISPR-Cas systems, they possess a reliance on near-perfect 
complementarity between the crRNA and a DNA target, and a subtype-specific protospacer 
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adjacent motif (PAM) 34-36. Point mutations in the PAM or the PAM-proximal region of the 
protospacer (denoted as the ‘seed’) can result in phages or plasmids that can escape CRISPR 
targeting and proceed to replicate despite a near perfect or perfect spacer match 37. 
 
Anti-CRISPR Genes in Pseudomonas aeruginosa 
In the human pathogen, Pseudomonas aeruginosa, prophages have been implicated in 
phenotypes such as toxin production and overall virulence 38,39. However, the mechanisms by 
which P. aeruginosa prophages modulate the physiology of their hosts are poorly understood. 
An effort to discover and characterize novel prophage-mediated phenotypes in this organism led 
to the serendipitous identification of the first phage-encoded inhibitors of CRISPR-Cas function. 
A survey of 30 distinct P. aeruginosa prophages revealed many examples of superinfection 
exclusion 40. Surprisingly, examples were observed where a subset of integrated prophages 
licensed infection by a superinfecting phage, allowing a phage to infect the lysogenized host. 
This observation was highlighted by a >106 fold change in the efficiency of plating for phages 
that did not form plaques on the wild-type, unlysogenized strain, but were able to infect and 
replicate in the lysogenic strain 41. The same phages that could only infect the lysogenized host 
had been previously shown to be targeted by the natural type I-F CRISPR spacers in the very 
same wild-type strain 42, leading the authors to speculate that prophages were inactivating 
CRISPR-Cas function. By comparing the genomes of phages that were sensitive to the action of 
CRISPR and those that were inactivating it, an ‘anti-CRISPR locus’ was identified. Many related 
phages from a single phage family possessed genes in this locus, that were small (i.e. 150-450 
base pairs) and of unknown function. Despite overall synteny and broad conservation of gene 
sequences throughout the rest of these phages, the anti-CRISPR locus was quite diverse (Fig. 
1.1a). By testing these genes in isolation, five were attributed anti-CRISPR function, based on 
their ability to allow infection of a CRISPR-Cas targeted phage 41. These genes are now known 
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as acrF1-F5. In addition to being encoded by this closely related family of ‘Mu-like’ phages (i.e. 
phages that utilize transposition to replicate), homologs of these genes were also identified in 
conjugative islands and plasmids, suggesting a broad role in enhancing horizontal gene transfer 
in Pseudomonas 41,43.  
 
The P. aeruginosa type I-F CRISPR-Cas system also possesses non-canonical function, via an 
interaction with a prophage possessing a target sequence with five mismatches. This interaction 
leads to the inhibition of biofilm formation and swarming motility 44,45. Furthermore, it was shown 
that phages that should have been targeted by the system (i.e. they possessed perfect matches 
to spacer sequences) were unhindered in their ability to replicate 46. The inability of this system 
to block phage replication led to the conclusion that this CRISPR-Cas system did not perform 
canonical functions. In hindsight, it is now clear that the relevant phages being tested in this 
study possessed acr homologs that prevented the detection of CRISPR-Cas activity and the 
correction of the five mismatches to four or zero mismatches in phage DMS3 (which lacks an 
acrF gene) caused it to be targeted through canonical CRISPR-Cas activity 42. Recent work has 
revealed that the DMS3 prophage with five mismatches triggers an SOS response as a result of 
a self-targeting genome cleavage event, which causes death upon the initiation of group 
behaviors 47. Together, these results highlight that acrF genes are important both during lytic 
and lysogenic growth, to protect a phage with perfect or mismatched protospacer targets. 
During lysogeny, the constitutive expression of an acr gene generates an immunocompromised 
host, which is now sensitive to other phages that CRISPR would have previously blocked. While 
this seems maladaptive for the prophage and lysogen, the inhibition of CRISPR-Cas function is 
an obligate part of lysogenic survival as genome cleavage that would result from self-targeting 
of the prophage would be lethal in the absence of an anti-CRISPR. 
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In addition to the type I-F system, type I-E systems had also been identified in many P. 
aeruginosa genomes 46. While type I-F function was serendipitously identified in a widely-used 
lab strain (PA14), a strain with a functional type I-E system had to be actively searched for 
among sequenced strains possessing this system. Strains with active systems were identified 
by designing plasmids possessing protospacers and assessing transformation efficiencies. 
Ultimately, two P. aeruginosa strains with functional type I-E systems were found. Using one of 
these strains, it was then possible to discover four distinct type I-E anti-CRISPR (acrE1-4) 
genes 48. The acrE genes were found as genomic neighbors to the acrF genes in the same 
family of Mu-like prophages. In many cases, individual phages were identified that encode both 
an acrF and an acrE gene.  
 
The Discovery of anti-CRISPRs in Diverse Bacterial Species 
Anti-CRISPR loci in the P. aeruginosa Mu-like phages possess a stereotypical genomic 
architecture (Fig 1.1a), with 1-3 acrE/F genes followed by a highly conserved gene that is 
referred to as anti-CRISPR associated gene 1 (aca1). While the anti-CRISPR genes possess no 
significant shared sequence identity between them, aca1 homologs encode proteins with 95% 
sequence identity in this family of phages and only occur in phages that possess acr genes. 
While homologs of acrE/F genes have been found in diverse mobile elements within 
Pseudomonas species, homology searches did not identify any hits outside of this genus, 
making it difficult to predict whether ACRs are widespread. The conservation of aca1, however, 
provided a robust bioinformatics tool to identify novel acr genes both in and outside of 
Pseudomonas (Fig. 1.1b). Utilizing this conserved gene as a query, two new acrF genes 
(acrF6, acrF7) were discovered in Pseudomonas mobile elements. Excitingly, acrF6 homologs 
were discovered in diverse Gammaproteobacteria and some of these homologues proved to be 
active against the P. aeruginosa I-F system, representing the first anti-CRISPRs found outside 
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of the Pseudomonas genus. Also important, one acrF6 homologue was found next to a gene 
encoding an HTH-motif containing protein that was distinct from aca1, and was given the name 
aca2. Homologs of aca2 led to the discovery of acrF8-F10 in diverse organisms, as well as 
many other candidates that did not possess anti-CRISPR activity in P. aeruginosa. Together, 
these anti-CRISPR genes were identified broadly across the Proteobacteria phylum 49. Notably, 
some members of each new acrF genes discovered in this manner displayed a broad host 
range, inactivating the I-F systems of P. aeruginosa and Pectobacterium atrosepticum. The Cas 
proteins of the Pectobacterium system range from 40 to 60% sequence identity with their P. 
aeruginosa orthologues. This broad host range was a feature of only acrF1 and acrF2 from the 
original group. Furthermore, this study yielded the first dual specificity anti-CRISPR protein 
(acrF6Pae) which could also inactivate the type I-E CRISPR-Cas system 49. This work 
demonstrated the power of utilizing a “guilt by association” bioinformatics approach to discover 
small, novel genes of unknown function next to aca1/2 homologs as a method for the discovery 
of new anti-CRISPRs.  
 
The Discovery of Anti-CRISPRs Inhibiting Cas9 
Performing further BLAST searches with Aca2 led to a gene encoding a putative Acr in a strain 
of Brackiella oedipodus 50. This strain did not encode a type I CRISPR-Cas system, but did 
encode a type II-C (Cas9) system, leading to the hypothesis that this might be a Cas9 inhibitor. 
A homologue of this putative Acr was found in Neisseria meningitidis, which also possesses a 
type II-C CRISPR-Cas system (Fig. 1.1b). Subsequent experiments showed that these proteins 
did inhibit the N. meningitidis Cas9 system in its natural context, proving the existence of anti-
CRISPRs against a Cas9-based system. Further bioinformatic investigation uncovered two 
more families of anti-CRISPRs functioning to inhibit N. meningitidis Cas9 (NmeCas9). 
Excitingly, these anti-CRISPRs were also found to function in human cells to inhibit genome 
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editing mediated by NmeCas9. These studies were important in showing that Acrs were not 
limited to type I CRISPR-Cas systems. 
 
Upon acquisition of foreign DNA encoding an acr gene, one outcome is that a strain may now 
possesses an element in the genome with a target of the CRISPR-Cas system. For example, a 
temperate phage with a targeted protospacer and PAM can avoid CRISPR targeting by 
deploying an Acr protein, allowing integration and stable lysogeny due to continued production 
of the Acr protein. This results in a situation described as “self-targeting.” The continued 
expression of an Acr protein is now an essential process in this cell as loss of Acr expression 
will result in lethal genomic cleavage. This premise was utilized as a bioinformatics strategy to 
identify strains that possessed the first Acr proteins encoded in a Gram positive microbe 51. Four 
distinct inhibitors of the Type II-A CRISPR-Cas9 system in Listeria monocytogenes were 
identified (acrIIA1-4), guided by examples of genomic self-targeting (Fig 1.1c). Most acr genes 
in this system were encoded by prophages in L. monocytogenes genomes, with some acr 
homologs being found in distant phages and plasmids of L. monocytogenes and other 
Firmicutes. Two of these newly discovered Acr proteins (AcrIIA2 and AcrIIA4) were able to block 
function of the widely used S. pyogenes Cas9 both in an E. coli test system and in a genome 
editing assay in human cells. L. monocytogenes and S. pyogenes Cas9 are 53% identical, 
showing that AcrIIA proteins can also function against distinctive systems.  
 
The type II-A and type II-C Acrs together present important new additions to the Cas9 
engineering toolkit, derived from the phage-bacterium arms race. Much work remains to be 
done for the AcrIIA/C proteins to understand how widespread they are, how many distinct 
proteins perform this task, and what the evolutionary implications are for their presence.  
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Anti-CRISPRs are widespread 
While ~50% of bacteria possess CRISPR-Cas systems, an open question is whether any given 
system is active and able to respond to foreign DNA invasion 52. Although it is impossible to 
experimentally interrogate every microbe possessing a type I-F system, for example, one can 
utilize bioinformatics to predict whether a given system may be capable of being inactivated by 
known acr genes. In the I-F system, where ten acrF sequences are available, it appears that 
nearly every known I-F system it is possessed by a genus that also has a known acr gene or a 
is closely related one that fits those criteria 49. This suggests widespread inactivation of I-F 
CRISPR-Cas systems across its entire distribution. As the best-studied group of acr genes, this 
provides a hypothesis going forward, that every CRISPR-Cas system may possess a similar 
and concomitant abundance of acr genes throughout its distribution. 
 
The acrIIC genes were also found beyond the organism they were discovered in (N. 
meningitidis), suggesting the potential for widespread Type II-C CRISPR-Cas inactivation as 
well 50. The coverage was not as striking as the acrF genes, however, suggesting that there are 
likely acrIIC genes to discover. The acrIIA genes told a slightly different story, while homologs of 
acrIIA2-4 were found only in Listeria and Streptococcus prophages and plasmids, acrIIA1 
homologs were found broadly across the Firmicutes. This distribution included many species 
encoding Type II-A CRISPR-Cas systems, suggesting widespread inactivation of Cas9 in these 
organisms. As the discovery of new acr genes continues, it will be exciting to track where their 
homologs are encoded to determine what percentage of CRISPR-Cas systems are likely 
“inhibitable” and what this will mean for bacteria and phages on an evolutionary timescale. 
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Anti-CRISPR Gene Organization 
To defend against commonly encountered Type I-E and Type I-F CRISPR-Cas systems, many 
P. aeruginosa phages maintain an acrE gene alongside an acrF gene in their anti-CRISPR loci. 
The most interesting example of phage response to dual I-E and I-F CRISPR-Cas targeting is 
the evolution of the P. aeruginosa phage allele of acrF6 (acrF6Pae), which is a single protein 
possessing dual I-E and I-F inhibitory activity. This dual activity is unique to the P. aeruginosa 
phage allele, as acrF6 homologs from 5 other diverse bacteria did not inhibit the I-E system of 
P. aeruginosa. Interestingly, this anti-I-E activity could be abolished by a C-terminal truncation of 
the final 2 residues of the AcrF6Pae protein, all while leaving the anti-I-F activity of the protein 
unaffected. In contrast to the pervasive co-association of heterotypic Acrs in P. aeruginosa 
phages, examples of two acrF or acrE genes appearing together in the same genome is much 
rarer. The singular locus architecture with acrF co-association is the co-occurrence of acrF3 and 
acrF5. Interestingly, acrF3 often occurs in the absence of acrF5, but acrF5 is never found 
without acrF3. The functional significance of this unique genetic interaction is unknown and 
remains to be investigated. In contrast to I-F and I-E inhibitors, multiple II-A inhibitors are often 
encoded together in the same ACR locus. An estimated 75% of acrIIA loci encode more than 
one AcrIIA protein, whereas only approximately 7% of acrF loci have both acrF3 and acrF5 and 
there are no examples of acrE genes occurring in tandem. Dominating the acrIIA landscape is 
acrIIA1, which pervasively co-occurs with acrIIA2-4, demonstrating a potential multi-pronged 
attack on the L. monocytogenes CRISPR-Cas system. 
 
Mechanisms of Acr Function 
A notable feature of each family of Acr proteins is their lack of sequence similarity to any 
proteins of known function. Furthermore, besides being small (~50-150 amino acids), there are 
no common features among them. For these reasons, no insight into the mechanisms of Acr 
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function could be gained until experimental studies on individual Acrs were undertaken. The first 
such study provide an in vitro mechanistic characterization of AcrF1, F2 and F3 53. It was shown 
that each of the Acrs functions through a different mechanism. AcrF1 and AcrF2 both bound to 
the type I-F CRISPR-Cas (Csy) complex, but they did this by binding to different subunits of the 
complex (Fig 1.2). AcrF1 bound with a stoichiometry of 2 or 3 to the Cas7f (Csy3) subunit, 
which is present in 6 copies in the Csy complex. By contrast, AcrF2 bound to the Csy complex 
with a stoichiometry of 1, and interacted with the Cas8f (Csy2):Cas5f (Csy1) heterodimer. Both 
of these Acrs inhibited the DNA-binding activity of the Csy complex. However, AcrF2 directly 
competed with DNA for a site on the Csy complex, while AcrF1 interacted with a site removed 
from the DNA interaction site. Interestingly, AcrF1 could still form a complex with the DNA-
bound Csy complex if the DNA was added first. AcrF3 directly bound to the Cas3 helicase-
nuclease protein and prevented its recruitment to the Csy-DNA complex. AcrF4 bound to the 
Csy complex like AcrF1 and AcrF2 but specific details were not obtained 53. 
 
To gain structural resolution of AcrF3 interacting with Cas3, co-crystal 54 and cryo-EM 55 
structures were recently published. These structures revealed an AcrF3 dimer, where each 
monomer makes multiple asymmetric contacts with many residues and domains of Cas3. This 
effectively covers an entire face of the Cas3 protein, approximately 2,500 Å2 in surface area 54. 
The large size of this interaction interface suggests that individual mutations in Cas3 are unlikely 
to successfully evade AcrF3 function. In contrast to these results with AcrF3, an NMR solution 
structure of AcrF1 coupled with extensive mutagenesis revealed a small patch of the protein 
was required for function 56. A single tyrosine to alanine mutation at position 6 of AcrF1 was 
sufficient to inactivate  anti-CRISPR function in vivo and in vitro. These two Acr protein 
structures highlight the diversity of structure and mechanism of these inhibitor proteins.  
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Other Possible anti-CRISPR Mechanisms 
In contrast to newly discovered CRISPR/anti-CRISPR antagonism, other forms of bacterial 
immunity/counter-immunity are better studied and the specific details of counter-immunity 
evolution are better understood 57. Across diverse systems, bio-mimicry is employed as a 
mechanism to inhibit immune activity. This leads us to hypothesize that Acr proteins could have 
evolved by similar mechanisms of bio-mimicry and bacterial gene hi-jack.  
 
Nucleic acid mimics: Restriction enzymes comprise the bacterial “innate” immune system and 
have been studied for many years 58. Diverse inhibitors of restriction enzyme immunity have 
been discovered, many which ultimately function by shielding the phage DNA from enzymatic 
attack using base modification 59. However, other inhibitors work by mimicking phage DNA and 
tightly sequestering restriction enzymes 60. The T7 ocr gene, which is an immediate-early gene 
that T7 uses to inhibit restriction activity in its E. coli host is highly acidic and structurally 
resembles 24 bp of bent B-form DNA61. Similarly, the ardA gene, a widely distributed inhibitor of 
Type I restriction system, functions as a homo-dimer that mimics a 42 bp stretch of B-form DNA 
62. Viral bio-mimicry of DNA is also seen in eukaryotic systems, where a virally encoded DNA 
mimic binds histones and is hypothesized to disrupt nucleosome assembly and prevent repair of 
DNA breaks 63. 
 
Like restriction enzymes, CRISPR-Cas systems bind DNA and in principle, should be 
susceptible to inhibition by DNA mimics. DNA-binding activities that are independent of the 
sequence of the spacer-derived crRNA (i.e. the PAM site) ascribed to both type I and II 
CRISPR-Cas systems could provide a weakness for Acr DNA mimics to exploit. While inhibitors 
of RNA-binding CRISPR-Cas systems 64 have not yet been reported, RNA bio-mimicry could 
similarly function as an  anti-CRISPR strategy. Furthermore, though RNA-based mechanisms of 
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anti-CRISPR activity have not been discovered, we hypothesize that virally encoded small 
RNAs could mimic crRNAs and interfere with CRISPR activity. Specifically, crRNA mimics could 
function by outcompeting bona-fide crRNAs for Cas proteins during CRISPR-complex 
assembly, or by directly displacing crRNAs in pre-loaded complexes. Interestingly, some 
Clostriduim phages carry CRISPR arrays, the biological function of which is unknown 65.  
 
Cas genes as proto-Acrs: Horizontal gene transfer between phages and host bacterial species 
is pervasive, and CRISPR-Cas elements have been found in phage genomes previously. In a 
striking example of horizontal Cas gene transfer, Vibrio cholerae phages acquired a I-F CRISPR 
Cas system which they deploy to inhibit a novel V. cholerae DNA-based anti-phage immune 
system 10. Since Cas proteins interact in complex with each other, an Acr that mimics a Cas 
protein or Cas protein motifs could compete with or disrupt these bona fide Cas-Cas 
interactions. Despite these predictions, the structures of P. aeruginosa Acr proteins, AcrF1 56 
and AcrF3 54,55 bear no obvious resemblances or topology similarities to any of the P. 
aeruginosa Cas proteins for which there are structures: Cas1, Cas2-3, or Cas6 18,54,66. Further 
structural characterization of Cas:Acr protein interactions is urgently needed, especially for the 
multi-protein complexes utilized in type I systems as the structural intricacies of this complex 
may be absent without the interaction partners and crRNA present. This information will help 
illuminate the currently obscure evolutionary history of Acr proteins. 
 
Anti-CRISPRs as Modifiers of CRISPR-Cas Function 
The nuances of AcrF function go far beyond simple inhibition of interference, as these proteins 
have the ability to enable or disable new functions that were not initially predicted. For example, 
the inhibition of Cas3 recruitment mediated by AcrF3 converted the CRISPR system into a 
sequence-specific transcriptional repressor (CRISPRi) when the system was targeted to a 
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promoter region. This repression presumably occurred because the crRNA-guided complex 
could bind DNA and block RNA polymerase recruitment, but DNA cleavage did not occur 53. 
Type I CRISPRi had previously been demonstrated in the type I-E system via the deletion of the 
Cas3 nuclease 67,68 and in the Type II system by catalytic inactivation of Cas9 69,70. This 
demonstrates the ability of an Acr protein to leave CRISPR-Cas function partially intact and may 
therefore enable new functionalities such as “natural CRISPRi.” Additionally, the discovery of 
priming acquisition (a mechanism of spacer acquisition that requires all components of the 
CRISPR-Cas system), connected the spacer acquisition and interference pathways, which were 
previously thought to be separate 14. With this connection, it became clear that while AcrF 
proteins bind to the interference factors in the Type I-F system (Csy complex, Cas3), this also 
functions to block new spacer acquisition 71. 
 
The recent discovery of Cas9 inhibitors (AcrIIA and AcrIIC proteins) that were both able to 
interfere with Cas9 gene editing activity in human cells 50,51 suggests that these also directly 
bind to Cas9. Indeed, AcrIIC1, 2 and 3 proteins all form direct physical interactions with type II-C 
Cas9 from N. menengitidis but not type II-A from S. pyogenes 50. These data broadly show the 
utility for Acr proteins to function in heterologous hosts with potential benefits such as enabling 
CRISPRi (Cas3 inhibition) and providing an off-switch for gene editing applications and dCas9-
based CRISPRi applications. 
 
While direct interactions with Cas proteins present a logical solution for phages to CRISPR-Cas 
based immunity, we envision many future strategies to achieve this end result. For example, 
base modifications have been previously shown to block Type II 72 and Type I 73 immunity, 
although the Type II results seem to depend on the guide RNA design 74. Certain mechanisms 
of phage injection and replication may also be recalcitrant to CRISPR targeting, as was recently 
shown for phage T5, which injects its genome gradually and therefore only ~10% of the DNA is 
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a substrate for effective CRISPR-Cas immunity 73. Additionally, Acr proteins that conduct 
enzymatic inactivation or destruction of Cas proteins or the crRNA, or transcriptional repression 
of any component of the CRISPR-Cas system might sufficiently shift the balance in favor of the 
phage during infection.   
 
Anti-CRISPRs are phage accessory genes 
Phage genomes are highly mosaic, possessing distinct functional “modules” with unique 
evolutionary histories 1,75,76. Individual modules are assorted into phage genomes through 
diverse mechanisms of DNA recombination and/or ligation, and high fitness combinations being 
selected for, whereas low fitness assemblages are purged from the phage population. The 
frequency with which modules are moved in or out of genomes of related phages creates a 
conservation pattern that allows for the designation of core and accessory genes across a 
population of related phages. The core genome contains genes that are essential for lytic or 
lysogenic replication under all conditions and genetic backgrounds, such as genes encoding the 
phage virion components, lysis proteins, or repressor proteins 77,78. While core genes are 
broadly conserved among groups of related phages, accessory genes will often be conserved in 
only subsets of phages, and may also be observed sporadically in diverse groups of phages 79. 
Accessory genes may be essential under some conditions or provide a fitness advantage to the 
phage or its host (in the case of a prophage) under only certain conditions. In some cases, 
accessory genes have been referred to as “morons” and this term may be used to specifically 
refer to accessory genes of phages 5,80,81 as core and accessory genes are also a feature of 
bacterial genomes. The specific combination of accessory genes in a given phage genome 
likely reflects its adaption to a specific host or niche, meaning that deletion of accessory genes 
often will not result in phenotypic change in standard laboratory growth conditions on a 
permissive host. Indeed, acr genes are conditionally essential; they can be deleted or disrupted 
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without phenotypic consequence, when infecting a bacterial host lacking a CRISPR-Cas system 
or CRISPR spacers targeting that specific phage.  
 
The best-studied phage accessory genes increase the fitness of the bacterial host during 
lysogeny, participating in adaptive “lysogenic conversion”82,83 . Historically studied for their role 
in bacterial pathogenesis, diphtheria toxin, cholera toxin, and Shiga toxin are famous examples 
of prophage encoded accessory genes that dramatically alter the behavior of their hosts. Other 
conditionally essential phage accessory genes are involved in inter-phage warfare, preventing 
superinfection by a competitor phage. A recently published paper from the Hatfull group 
highlights the diverse roles that phage accessory genes play in during inter-phage antagonism 
84. The authors first discovered a mycobacteriophage toxin/anti-toxin (TA) module that inhibited 
superinfection by competitor mycobacteriophages. The TA module, composed of toxic pp(p)Gpp 
synthetase and associated anti-toxin, inhibits replication of incoming superinfecting phages by 
promoting pp(p)Gpp synthesis, leading to cessation of cell growth and preventing lytic 
replication. The group then discovered accessory gene alleles encoded in a competitor phage, 
which had evolved to counter this prophage encoded defense system. This accessory gene 
specifically inhibited the anti-phage activity of the TA module, presumably by preventing TA 
dissociation. This impressive example of phage-host interactions stands out as an example of 
Red Queen selection dynamics, which predict counter-adaptation as a requirement for survival 
in “arms races” such as these 85. Previous examples of these dynamics have been 
demonstrated in both phages and eukaryotic viruses 86,87. 
Anti-CRISPRs are another clear example of Red Queen dynamics at play in the phage 
accessory genome. These anti-immunity genes were first discovered in the genomes of a group 
of highly syntenic Mu-like phages with only a few pockets of genomic diversity – their accessory 
gene loci 40,88. Interestingly, accessory gene loci appear in conserved locations across the 
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genomes of these Mu-like phages, despite the sequences of the genes in the accessory locus 
being distinct. The anti-CRISPR accessory locus exemplifies the “grab-bag” nature of these loci 
– many diverse inhibitor proteins are encoded at the same location in the phage genome (Fig 
1.1). It is interesting to broadly consider these loci as functional modules themselves – are 
genes in other syntenic accessory loci also inhibiting the same bacterial process through 
different mechanisms in these phages? In striking similarity to the P. aeruginosa Mu-like 
phages, the L. monocytogenes phages encoding acrIIA genes have highly syntenic genomes 
with conserved functional modules interspersed with accessory gene pockets. The diverse 
acrIIA genes are similarly anchored by a conserved gene (acrIIA1) encoding predicted HTH 
protein 51. In contrast to the P. aeruginosa Mu-like phage acr locus, not all of the accessory 
genes encoded in the L. monocytogenes “acr locus” have been demonstrated to have ACR 
function. It is worthy of follow-up to determine the functions of these genes. Similarly, many 
candidates from the 2016 survey of aca1-possessing loci across diverse prophages and mobile 
genetic elements in Proteobacteria discovered genes that did not exhibit anti-CRISPR activity 
when tested against the P. aeruginosa I-E and I-F CRISPR-Cas systems 49. These proteins of 
unknown function are strong candidate inhibitors for other types of bacterial anti-phage 
immunity.  
 
The striking diversity of acr genes across even closely related phages generates several 
questions- where were these diverse genes acquired from, and how did they evolve? Currently, 
no known “proto-anti-CRISPRs” have been discovered, and the evolutionary path of these novel 
proteins is mysterious. Analyses of the primary anti-CRISPR amino acid sequences have 
yielded have no recognizable domains or motifs, and likewise structural characterization of 
AcrF1 and AcrF3 has provided little insight into the origins of these inhibitors 54-56.  
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Why are anti-CRISPR Genes so diverse? 
Many distinct acr genes have been identified thus far for I-E, I-F, II-A, and II-C systems. While 
the evolutionary history of anti-CRISPRs may be currently enigmatic, acr diversity presents an 
intriguing question: why there so many acr genes? We propose two non-mutually exclusive 
hypotheses to explain acr diversity:  
I) Distinct acrs confer distinct, niche-specific fitness advantages to their host phage  
II) acr diversity is a form of “distributed anti-immunity”  
 
Hypothesis I: Like other phage accessory genes, the specific assemblage of acr genes on a 
given phage represents a snapshot of a unique set of fitness challenges experienced by that 
phage. As an obvious example, the combination of acrE and acrF genes found in P. aeruginosa 
phages reflects that they have likely cycled through hosts with both I-E and I-F CRISPR-Cas 
systems. It is less clear, however, what specific fitness advantages might be associated with 
using one particular AcrF protein over another.  One immune inhibitor may impact phage fitness 
differently than another, and likewise the same Acr on a distinct type of genetic parasite (like a 
plasmid or mobile island) likely also has different fitness outcomes for the parasite. Non-lytic 
conjugative elements impose different selective pressures on their hosts and thus would 
experience a different set of fitness costs and benefits associated with Acr deployment.  
 
Dependent on the host Cas protein sequences and expression levels, the potential for 
weakness in an Acr protein’s mode of action provokes the hypothesis that incomplete inhibition 
of CRISPR-Cas immunity may result. Although counterintuitive, this could benefit a phage by 
maintaining a population of infection-susceptible hosts and reducing selection for the evolution 
of alternative forms of anti-phage immunity such as phage receptor loss. Indeed, it has been 
shown that under the presence of high phage burden, surface modifications are favored over 
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CRISPR-based immunity 89. Furthermore, we also imagine the potential for Acr proteins to 
synergize with each other when two acr-encoding phages infect the same bacterial cell. By 
targeting different steps in CRISPR interference, infections with heterotypic acr genes could 
lead to more viral replication than homotypic infections, selecting for the maintenance of diverse 
acr genes in a viral population and facilitating accessory gene exchanges between closely 
related phages. 
 
Hypothesis II: Diverse acr genes limit evolution of anti-anti-CRISPR (anti-Acr) mechanisms. An 
important facet of CRISPR immune function is the paradigm of distributed immunity, which is 
selection for the co-existence of many, equally fit, immune alleles in a population. This theory of 
CRISPR immunity was proposed first by the Whitaker group and tested using modeling 
approaches and experimentally evolved microbial populations of Streptococcus thermophilus 90. 
The distributed CRISPR immunity hypothesis is that viral predators select for the maintenance 
of a diverse spacer repertoire distributed across a microbial population. It is simple for a virus to 
escape targeting of one CRISPR spacer: a single point mutation can fully disable CRISPR 
immunity 37. However, distribution of many targeting spacers across a microbial population 
prevents individual viral escaper genotypes from emerging. Likewise, no single spacer will 
dominate the CRISPR landscape because immunity functions on the level of microbial 
populations not individual microbial genotypes.  
 
To test the importance of distributed immunity, P. aeruginosa Mu-like phage DMS3 and 
artificially assembled populations of P. aeruginosa with varying degrees of spacer diversity 
distributed across the bacterial population 91. They found that low diversity populations of P. 
aeruginosa with 1, 6, or 12 spacer genotypes routinely selected for the emergence of escaper 
phages that had presumably accumulated point mutations across protospacer regions. In 
contrast, high diversity populations with 24 or 48 spacer genotypes drove the DMS3 phage to 
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extinction. In the case of high-diversity populations, only Acr deployment could protect the 
phage from CRISPR immunity. We invoke a hypothesis of distributed anti-immunity to describe 
anti-CRISPR diversity. By maintaining a diverse repertoire of acr genes, viral populations limit 
the emergence bacterial anti-Acr mechanisms, such as point mutations in the target Cas 
protein. We next consider potential mechanisms for the emergence of anti-Acr strategies. 
 
Putative anti-anti-CRISPR mechanisms 
Acquisition of new CRISPR systems: CRISPR-Cas systems are diverse immune systems. 
Currently, there are six broad types of CRISPR-Cas systems which can be further subdivided 
into many subtypes 20,92. One of the simplest mechanisms by which bacteria could evolve to 
overcome phages with subtype specific acr genes is to accumulate multiple types of CRISPR-
Cas systems. In order to survive, a phage would need to inhibit all systems. There are many 
examples of bacteria that have accumulated multiple types of CRISPR-Cas systems. 
Streptococcus thermophilus, the first organism in which CRISPR-Cas activity was 
demonstrated, has 3-4 different CRISPR-Cas systems: two Type II-A systems, a Type III-A 
system, and sometimes a Type I-E system 93,94. It is unknown if acr genes have selected for this 
CRISPR diversity in S. thermophilus, however it is notable that thus far acr genes inhibiting both 
II-A and I-E CRISPR systems have been characterized. In contrast, no Type III anti-CRISPR 
has been discovered. Similar to S. thermophilus, Serratia sp. ATCC39006 carries an active I-E, 
I-F, and III-A CRISPR systems, and these diverse CRISPR systems were recently discovered to 
be regulated coordinately by quorum sensing 95. Again, it is unknown if Acr proteins have driven 
selection for Serratia to carry multiple CRISPR-Cas systems, however at least one acrF gene 
(acrF8) is found in Serratia marcescens genomes 49. Finally, in P. aeruginosa, acquisition of 
multiple CRISPR subtypes may also be driven by CRISPR/Acr warfare. P. aeruginosa has both 
Type I-F and Type I-E CRISPR-Cas systems, which often co-occur in the same genome. Less 
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frequently, P. aeruginosa genomes contain Type I-C CRISPR-Cas systems that are mobilized 
on an integrative and conjugative element (ICE).  I-C and I-F also co-occur in P. aeruginosa 
genomes, but there are no examples yet of genomes carrying all three 43. Currently, no anti-I-C 
anti-CRISPRs have been described.  
 
Mutational escape: The anti-CRISPRs that have been biochemically characterized bind 
specific surfaces on Cas proteins 53-55. By mutating these surfaces, bacteria could hypothetically 
evolve Acr resistant CRISPR systems. By employing diverse inhibitors that bind to unique 
surfaces on CRISPR-Cas proteins, a population of viruses will limit accumulation of such 
CRISPR-Cas escape mutations that could allow anti-CRISPR escape. Interestingly, in the co-
crystal of the AcrF3 dimer bound to its Cas3 target, the AcrF3 dimer makes many contacts 
across the face of the Cas3 protein, suggesting that many Cas3 mutations would be required to 
disrupt the AcrF3/Cas3 interaction 54.  More information about the residue-specific interactions 
between Acrs and Cas proteins will be critical to identify Acr resistant CRISPR-Cas systems.  
 
Regulatory changes: The biochemically characterized anti-CRISPRs bind stoichiometrically to 
their Cas protein targets. Interestingly, overexpression of the type I-F CRIPSR-Cas complex 
subunits in P. aeruginosa functions as an anti-ACR mechanism against the phages that use Acr 
proteins that bind this complex. In contrast, AcrF3, which targets the recruited Cas3 effector 
nuclease is not affected by increasing the intracellular concentration of proteins that it does not 
bind 53. This shows that Acr proteins can be overwhelmed by shifting intracellular Cas protein 
concentrations, and suggests the possibility for bacteria to overcome Acrs by overexpressing 
components of CRISPR-Cas systems. Multiple papers have reported different pathways 
involved in regulation of CRISPR-Cas systems in diverse bacteria 95-98. In each case, CRISPR-
Cas is dynamically regulated, suggesting a cost to constitutive CRISPR expression. We 
hypothesize that Acr proteins that target CRISPR-Cas subunits more toxic to overexpress would 
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have a selective advantage in this scenario. For instance, both Cas3 and Cas9 nucleases have 
the potential for genomic DNA cleavage, so Acr proteins that target these Cas proteins may be 
less susceptible to inhibition by CRISPR regulatory changes. Furthermore, some CRISPR 
systems are strongly induced during phage infection 99,100. At first glance, this can be interpreted 
as enhanced immune activity, but this could also present a mechanism to overwhelm inhibitor 
proteins deployed by the phage.  
 
Dedicated anti-CRISPR inhibitors: Bacteria may possess dedicated inhibitors of Acr function, 
which prevent target binding or cause Acr protein degradation. Alternatively, blocking acr 
expression may also be possible, despite acrs themselves being diverse in sequence and 
mechanism, a commonality amongst them is a shared regulatory environment. By targeting 
conserved, cis-acting DNA elements such as promoters, operators, and terminators required for 
acr expression, the bacterial cell could shift the balance in favor of CRISPR. For example, I-E, I-
F, and II-C anti-CRISPRs have conserved associated proteins aca1, aca2, and aca3 (of 
unknown function), whereas Type II-A anti-CRISPR loci often carry acrIIA1. Though the 
functional relevance of these associated proteins is currently unknown, they are strikingly 
conserved relative to their associated acr genes and could potentially represent the Achilles 
heel of an otherwise rapidly evolving system. A summary of these putative mechanisms for anti-
CRISPR evasion is provided in Fig.1.3. 
 
CRISPR meets anti-CRISPR in lysogeny 
Anti-CRISPRs are widespread across bacterial genomes. A recent report estimates that 64% of 
449 P. aeruginosa I-F systems are inhibited by chromosomally encoded acrF genes 49. The 
same study concluded that the full diversity of I-F systems across the phylum Proteobacteria is 
potentially able to be inhibited by known anti-CRISPRs. A separate analysis of P. aeruginosa I-
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E systems estimates that 53% of 81 I-E systems are inhibited by acrE genes 43. Similarly, >50% 
of II-A systems in L. monocytogenes are estimated to be inhibited by the recently discovered 
acrIIA genes. Though CRISPR-Cas systems are commonly inhibited by Acr proteins, the 
consequences of CRISPR/Acr co-occurrence are relatively unexplored.  
 
Self-targeting: The most striking sign of inhibition of CRISPR-Cas activity is the stable co-
existence of a CRISPR spacer and its target in the same cell. AcrIIA proteins were discovered 
using this strong genomic signature of “self-targeting” and this will likely be a useful strategy for 
the discovery of novel Acr proteins 51. In this scenario, an acr is now an essential gene of the 
lysogen, as anti-CRISPR loss will trigger direct CRISPR autoimmunity. Type I and II CRISPR-
Cas cannot distinguish between chromosomal “self” from incoming phage. In contrast, type III 
CRISPR-Cas systems, in which CRISPR activity is dependent on target transcription, have 
been demonstrated to conditionally tolerate their prophages with perfect protospacer matches 
101. Self-targeting is likely prevalent in bacterial genomes, and the phenotypic consequences of 
this potential autoimmune scenario are unknown. 
 
CRISPR-Cas alternative functions: There is increasing evidence pointing toward CRISPR-
Cas components (protein or RNA) performing alternative non-immunity-related functions 102. In 
the pathogen Franciscella novicida, non-canonical activity of CRISPR-Cas effector protein Cas9 
in association with a small CRISPR-Cas associated RNA (scaRNA) and the tracrRNA directly 
regulate levels of a virulence-associated transcript through base paring with the RNA target 103. 
It is currently unknown if F. novicida genetic parasites employ acr genes, but our current 
knowledge of Type II inhibitors suggests the potential for undiscovered acrIIB genes to impact 
virulence regulation in F. novicida. Furthermore, a recent publication has shown RNA targeting 
in the P. aeruginosa Type I-F CRISPR-Cas system, where a mismatched crRNA guides 
degradation of the lasR transcript, a master transcriptional regulator in P. aeruginosa 104. This 
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non-canonical, RNA-directed CRISPR-Cas activity is dependent on both the I-F CRISPR-Cas 
complex and recruited effector nuclease Cas3. Do endogenous Acr proteins disrupt non-
canonical CRISPR activity as well as canonical immunity functions? Given the widespread 
distribution of acrF genes are in P. aeruginosa and beyond 49, acr genes have the potential to 
profoundly impact the biology of their bacterial hosts. It will be very interesting to see if acr 
genes can inhibit, alter, or enable alternative functions, and what the evolutionary 
consequences of these interactions may be.  
 
Horizontal gene transfer 
CRISPR-Cas immune systems, which destroy foreign DNA, can act as barriers to horizontal 
gene transfer (HGT). While inhibition of viral parasites is an obvious adaptive function of a 
CRISPR-Cas system 27,94, the exclusion of potentially beneficial foreign DNA, such as a 
prophage 83, can render a CRISPR-Cas system disadvantageous, and selection for CRISPR-
Cas loss or inhibition can occur. By inhibiting CRISPR-Cas activity, chromosomally encoded 
acrs should enable foreign DNA acquisition in their hosts. HGT is pervasive in bacteria and has 
had a profound impact on shaping bacterial genomes, suggesting a strong potential cost to 
CRISPR-Cas activity and large potential benefit to anti-CRISPR acquisition. 
 
While individual examples of CRISPR excluding HGT mediated by plasmids, prophages, and 
through natural transformation have been shown 105-108, it has been difficult to extrapolate these 
individual examples to broad principles of bacterial genome evolution. In 2015, the Koonin 
group performed a bioinformatics study, analyzing CRISPR-Cas activity (using CRISPR array 
length as a proxy for activity) and HGT across 1399 microbial genomes 109. The authors found 
no evidence that CRISPR-Cas activity inhibited HGT on evolutionary time scales. Instead, they 
found that the best predictor of HGT was growth temperature, with lower genetic diversity at 
hotter temperatures. This counterintuitive finding suggests that propensity for HGT is an intrinsic 
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property of an organism and its ecological niche, and that CRISPR-Cas may exert its fitness 
impacts on the short-term population level rather than on long-term evolutionary timescales.  
 
Emphasizing the population level importance of CRISPR-activity on HGT, a 2015 comparison of 
CRISPR-Cas distribution and HGT across a population of P. aeruginosa isolates demonstrated 
that CRISPR-Cas activity significantly restricted genome size 43. Importantly, each P. 
aeruginosa strain was only considered to be immune-competent if it had a CRISPR array, Cas 
genes, and lacked chromosomally encoded acr genes. The group showed that P. aeruginosa 
strains with active I-E and I-F CRISPR-Cas systems had genomes that were on average 300 
kbp smaller than P. aeruginosa strains with no CRISPR-Cas systems. Fascinatingly, the authors 
also showed that P. aeruginosa strains with acrE or acrF genes had genome sizes that, on 
average, were not different in size compared to strains with no CRISPR-Cas system. Despite 
CRISPR inhibition likely being a relatively recent event in the evolutionary history of these 
bacterial strains, their HGT profile was similar to that of a strain that had presumably been 
without CRISPR for much longer. This result demonstrates the short-term, population-level 
impacts of CRISPR-Cas activity on bacterial genomes and emphasizes the rapid impacts that 
acrs can have on the biology of their host bacteria.  
 
The rapid acquisition of additional mobile genetic elements (MGEs) after CRISPR-Cas inhibition 
facilitate interactions amongst multiple MGEs. With multiple MGEs being more likely to be stable 
in the same cell, this could increase the horizontal transfer of new genes, including acrs 
themselves. It is interesting to consider the strong impacts that acr genes could have on 
shaping the accessory genomes of their host phage by “opening the door” to downstream 
infection. CRISPR inhibition of bacterial immunity could also have negative fitness impacts for 
the prophage, as the immune-compromised bacterial host could be infected and killed by a 
superinfecting competitor phage. 
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Not all phages have acr genes, suggesting that there may also be fitness costs to Acr action, 
such as licensing superinfecting phages. Interestingly, many of the Mu-like Acr phages in P. 
aeruginosa utilize diverse mechanisms to inhibit superinfection of other phages 40,110, which 
likely ameliorates some costs of host-immune compromise. As phage accessory genomes 
become better defined, it will be interesting to correlate the presence of superinfection exclusion 
genes with the presence of acr genes. Such complex genetic interactions in the phage 
accessory genome have likely profoundly shaped phage evolution, and may in part control anti-
CRISPR distribution across phage populations.   
 
Conclusion 
CRISPR-Cas immune systems are a relatively recent discovery in the arms race between 
phages and their hosts, but are likely ancient players in this battle. This new field has had a 
massive impact on our understanding of microbial evolution, phage biology, and horizontal gene 
transfer. Also remarkable is the elegance of many distinct, adaptive, sequence-specific RNA-
guided nuclease systems possessed by bacteria, with some of them currently revolutionizing 
human gene editing and therapy. Anti-CRISPRs are an even more recent addition to the 
CRISPR story and are fascinating for many reasons, providing new insights into how CRISPR-
Cas systems work, and how CRISPR systems and bacterial genomes have co-evolved with the 
moving target of mobile DNA. While it is still early, we have already seen examples of both 
CRISPR and anti-CRISPRs shaping bacterial population by dictating the horizontal DNA that is 
acquired versus what is excluded. Furthermore, as CRISPR has revolutionized gene editing, 
anti-CRISPRs have provided new biotechnological resources in our efforts to precisely edit the 
human genome and develop new tools to probe it. Future work should focus on the discovery of 
new anti-CRISPRs that inhibit distinct CRISPR-Cas systems, deciphering their mechanisms of 
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action and studying the counter response from CRISPR-Cas systems to combat anti-CRISPR 
emergence.  
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Figure 1.1  Anti-CRISPR (acr) locus organization.  
Stereotypical organizations of acr loci encoded by phages and mobile genetic elements (MGEs) 
are shown. Unique acr genes are named and shown in color, whereas non-acr genes are 
	 40 
shown in gray and are annotated with predicted functions when possible. (a) Pseudomonas 
aeruginosa Mu-like phage acr locus. The acr genes are all integrated at the same locus 
between two highly conserved structural genes (gray) that are homologous to Mu phage gene G 
and Mu phage protease (I)/scaffold (Z) genes. Many loci encode both type I-E (AcrE1–4) and I-
F (AcrF1–5) Acr proteins, all adjacent to the conserved anti-CRISPR-associated gene 1 (aca1). 
A representative phage is indicated for each unique locus architecture. Panel adapted from 
Reference 48. (b) acr loci in diverse Proteobacteria are shown. These acr loci do not share a 
common “genomic neighborhood,” but all are anchored by HTH-encoding anti-CRISPR-
associated genes (aca1–3). Representatives of each acr-aca association are shown in the 
indicated species. Panel adapted from Reference 49. (c) Listeriophage acrIIA locus. The 
listeriophage locus is near the left end of the integrated prophage genome and a highly 
conserved endolysin gene (lys). All listeriophage acr loci are anchored by the HTH-encoding 
gene acrIIA1. Panel adapted from Reference 51. 
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Figure 1.2  Mechanisms for anti-CRISPR protein function 
 CRISPR-Cas immune function is broken down into five distinct processes, shown in brown 
boxes. Acr proteins that inhibit these processes are shown for both type I and type II CRISPR-
Cas systems. All characterized type I-F Acr proteins (AcrF1–5) have been demonstrated to 
inhibit both adaptation and immunity by preventing either foreign DNA recognition (AcrF1, 
AcrF2, and AcrF4) or Cas3 nuclease recruitment (AcrF3). AcrIIA2, AcrIIA4, and AcrIIC3 prevent 
DNA target binding by Cas9. All anti-CRISPRs are defined by their ability to ultimately prevent 
foreign DNA destruction, though the mechanisms by which most of them accomplish this task 
are still unknown. Abbreviations: crRNA, CRISPR RNA; R, repeat. 
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Figure 1.3  Anti-anti-CRISPR mechanisms 
To inhibit CRISPR-Cas immunity, acr genes need to be transcribed and translated inside a host 
cell. Currently, there are no described mechanisms by which bacterial hosts perturb anti-
CRISPR transcript or protein levels, but AcrF proteins can lose efficacy when the intracellular 
concentration of Cas protein targets is increased. Cas mutations that lower or abolish Acr 
binding affinity for the Cas target could also serve to shift the balance in favor of the CRISPR-
Cas system, as could protein inhibitors that sequester Acr proteins and prevent them from 
binding their Cas targets. Lastly, deployment of multiple types of CRISPR-Cas systems is a 
mechanism by which cells can protect themselves from subtype-specific Acr proteins and may 
in part explain the accumulation of multiple CRISPR-Cas system types and subtypes in diverse 
bacteria. 
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Chapter 2: Bacteriophage cooperation suppresses CRISPR-Cas3 and Cas9 immunity 
 
ABSTRACT 
Bacteria utilize CRISPR-Cas adaptive immune systems for protection from bacteriophages 
(phages), and some phages produce anti-CRISPR (Acr) proteins that inhibit immune function. 
Despite thorough mechanistic and structural information for some Acr proteins, how they are 
deployed and utilized by a phage during infection is unknown. Here, we show that Acr 
production does not guarantee phage replication when faced with CRISPR-Cas immunity, but 
instead, infections fail when phage population numbers fall below a critical threshold. Infections 
succeed only if a sufficient Acr dose is contributed to a single cell by multiple phage genomes. 
The production of Acr proteins by phage genomes that fail to replicate leave the cell 
immunosuppressed, which predisposes the cell for successful infection by other phages in the 
population. This altruistic mechanism for CRISPR-Cas inhibition demonstrates inter-virus 
cooperation that may also manifest in other host-parasite interactions. 
 
INTRODUCTION 
Bacteria and the viruses that infect them (phages) are engaged in an ancient evolutionary arms 
race, which has resulted in the emergence of a diversity of CRISPR-Cas (clustered regularly 
interspaced short palindromic repeats and CRISPR-associated genes) adaptive immune 
systems 1. CRISPR-Cas immunity is powered by the acquisition of small fragments of phage 
genomes into the bacterial CRISPR array, the subsequent transcription and processing of these 
arrays to generate small CRISPR RNAs, and the RNA-guided destruction of the phage genome 
2-5. The destruction of foreign DNA by CRISPR-Cas has been shown to prevent the acquisition 
of plasmids, DNA from the environment, phage lytic replication, and prophage integration 2,3,6-9. 
In bacterial populations, these systems provide a fitness advantage to their host microbe when 
phage are present in the environment 10,11.  
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To combat the potent action of RNA-guided CRISPR-Cas nucleases, phages have developed 
inhibitor proteins called anti-CRISPRs (Acrs). Acr proteins have been discovered in phages, 
prophages, mobile islands, and core genomes across many distinct bacteria and archaea 12-14. 
Specific Acr proteins that inhibit Type I-F, I-E, and I-D CRISPR-Cas3 systems have been 
identified 14-17, as well as proteins that inhibit Type II-A and II-C CRISPR-Cas9 systems 18-20. 
Phylogenetic studies indicate that these proteins are likely ubiquitous in coevolving populations 
of bacteria and phages 13 and provide a significant replicative advantage to phages in the 
presence of CRISPR-Cas immunity 11.  
 
Anti-CRISPRs were first identified in phages that neutralize the Pseudomonas aeruginosa Type 
I-F system (anti-CRISPR type I-F, AcrIF1-5)15, and five more I-F anti-CRISPRs (AcrIF6-10) were 
subsequently identified in various mobile genetic elements 16. The I-F Csy surveillance complex 
(also called I-F Cascade) is comprised of an unequal stoichiometry of four proteins (Csy1-4) that 
assemble with a 60 nt CRISPR RNA (crRNA) guide 21-27. The Csy complex locates and binds 
foreign dsDNA targets complementary to the crRNA, then recruits a trans-acting 
nuclease/helicase protein called Cas2/3 to degrade the target 28-30. Anti-CRISPR proteins 
function by interacting directly with the Csy complex and inhibiting DNA binding, or bind to 
Cas2/3 and prevent nuclease-mediated degradation 31. The structures of Type I-F Acr proteins 
AcrIF1, AcrIF2, AcrIF3, and AcrIF10 have been solved in complex with their target proteins, 
revealing mechanistically distinct inhibitors that bind tightly to their targets 25-27,29,30,32. Together 
with the recent identification and characterization of proteins that inhibit Cas9, all characterized 
Acr proteins block phage DNA binding or cleavage 18,20,33-36.  
 
All AcrIF proteins are robust inhibitors of CRISPR-Cas activity when expressed from high copy 
plasmids prior to phage challenge, however this method of CRISPR-inactivation is not reflective 
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of anti-CRISPR deployment by phages in nature. When phage DNA cleavage has been 
assessed in vivo, it occurs in as little as 2 minutes 3, suggesting that phage genome degradation 
may outpace de novo Acr synthesis and function. We therefore hypothesized that successful 
inhibition of CRISPR-Cas immunity by Acr proteins during phage infection would be challenging, 
as all components of the P. aeruginosa immune system are expressed prior to phage infection 
6,15.  
 
Here, we demonstrate that complete CRISPR-Cas inactivation by a phage-produced Acr protein 
is challenging, and that the concentration of Acr proteins required to inactivate CRISPR-Cas is 
contributed by multiple phage genomes. While initial phage infections fail due to rapid genome 
degradation by the CRISPR-Cas system, Acr deposition prior to phage destruction causes 
cellular immunosuppression. If the cell is re-infected, Acr proteins from the initial phage infection 
enhance the likelihood of subsequent phage replication. We propose that pathogens can 
contribute to the “remodeling” of their host cell via rapid protein production, even if the initial 
infecting genomes are cleared, opening the door for their clones. 
  
RESULTS 
Anti-CRISPR proteins are imperfect CRISPR-Cas inhibitors 
We utilized the diversity of acr genes encoded by phages infecting P. aeruginosa to determine 
the mechanism of CRISPR-Cas neutralization during infection. Five natural phages, each 
encoding a single acrIF gene, were selected to represent acrIF1-IF4 and acrIF7 (acrIF5 does 
not exist as the sole acrIF gene on any phage, acrIF6, F8-F10 are not encoded by this phage 
family). Three of the five phages exhibited reduced efficiency of plaquing (EOP) on P. 
aeruginosa strain PA14, which possesses a naturally active Type I-F CRISPR-Cas system with 
1 or 2 spacers targeting these phages (Fig. 2.1A, WT:pEmpty normalized to plaquing on 
∆CRISPR). Overexpression of a targeting crRNA (WT:pSp1) exacerbated anti-CRISPR 
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inefficiency, limiting the replication of all phages by at least one order of magnitude. This 
suggests that Acr proteins are unable to fully protect their associated phage genome.  
 
To assess anti-CRISPR strength directly, an isogenic phage panel was generated by replacing 
the acrIE3 gene in the anti-CRISPR locus of phage DMS3m with single acrIF genes F1-F7 
(DMS3macrIF1-DMS3macrIF7). acrIF1-F5, and acrIF7 are all encoded by DMS3m-like phages in 
syntenic anti-CRISPR loci, while acrIF6 was discovered in a distinct type of P. aeruginosa 
phage. WT PA14 (1 spacer targeting DMS3m, “1sp”) and a PA14 derivative which acquired 4 
more spacers against DMS3m through laboratory evolution (“5sp”) were challenged with this 
panel of recombinant phages. For phages encoding acrIF1, F2, F3, F6 or F7, >90% of phage in 
the population failed to replicate (EOP=10-1) when faced with 5 targeting spacers (Fig. 2.1B). 
acrIF4 and acrIF5 were very weak, with 99.0-99.99% of phages failing to replicate, depending 
on the CRISPR spacer content. Phages must rely on acrIF genes when infecting the 5sp strain, 
as the acrIE3-encoding phage is unable to escape CRISPR targeting via protospacer mutation 
alone. We conclude that phages encoding anti-CRISPRs remain sensitive to CRISPR-Cas 
immunity, suggesting that anti-CRISPR deployment and action is an imperfect process. 
 
The observations above identified groups of “strong” and “weak” Acr proteins. We selected one 
representative from each group for downstream experiments, and a third Acr that does not 
target the I-F CRISPR system (i.e. AcrIE3), as a negative control. AcrIF1 was selected as a 
model strong inhibitor, as its mechanism and binding affinity are known (Csy complex binding, 
KD = 3 x 10-11 M 25,31). In contrast, AcrIF4 is a weak inhibitor that also binds the Csy complex 31, 
but with a significantly slower on-rate and faster off-rate compared to AcrIF1 (Fig. 2.1C, Fig. 
2.2).  
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Lytic replication requires a critical Acr protein concentration 
We next assessed the survival of bacterial populations when infected with phages that rely on 
apparently imperfect Acr proteins for survival. To assay the lytic cycle only, phages were 
prevented from entering lysogeny by knocking out the C repressor gene (gp1) in DMS3macrIF1, 
DMS3macrIF4, and DMS3macrIE3. The virulent (vir) phages were used to infect the 5sp strain in 
liquid culture, and bacterial growth measured. Given that AcrIF4 has a KD for its binding partner 
that is >4 orders of magnitude weaker than AcrIF1 for its binding partner, we reasoned that a 
higher concentration of phages encoding AcrIF4 may be required to inactivate CRISPR-Cas 
function. In the presence of CRISPR-Cas immunity, bacterial death only occurred at 
multiplicities of infection (MOI, input plaque forming units per colony forming unit) greater than 
0.02 (≥105 PFU) for acrIF1 (Fig. 2.3A) and greater than an MOI of 2.0 (≥107 PFU) for acrIF4 
(Fig. 2.3B). Phage replication observed here was due to Acr function, and not a result of phage 
escape mutations, as output phages remained as sensitive to CRISPR-Cas immunity as the 
input phage population (Fig. 2.4A-C). Furthermore, the phage encoding acrIE3 had no impact 
on bacterial survival when faced with CRISPR immunity (Fig. 2.3C), while in the absence of 
CRISPR, phages at all concentrations cleared bacterial cultures (Fig. 2.3D-F). These data 
demonstrate that Acr-mediated CRISPR-Cas inactivation requires a critical phage concentration 
that is inversely proportional to Acr strength.  
 
We hypothesized that the phage concentration dependence that dictates Acr success is 
achieved by the contribution of Acr proteins from multiple phage genomes in a single cell, which 
is not achieved at low MOIs. To this end, we rendered a subset of phages in the population non-
replicative Acr donors to test if Acr donation alone is sufficient to rescue a failing (i.e. low MOI) 
infection. The C repressor gene (gp1) and surrounding immunity region from a DMS3m-like 
phage (JBD30) was introduced into DMS3m phages, generating a hybrid phage. The replication 
of the hybrid phage could be specifically prevented by overexpression of the JBD30 C repressor 
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(gp1, Fig. 2.5A), a protein that does not interfere with DMS3m phage with wild-type immunity 
regions (Fig. 2.5B). This enabled the mixing of two independent phage populations: a sacrificial 
Acr “donor” that cannot replicate and a wild-type (replication competent) Acr “acceptor”.  
 
In the presence of donor phages encoding AcrIF1 (106 PFU, MOI = 0.2), we observed a striking 
contribution to CRISPR-Cas neutralization, despite the inability of this phage to replicate (Fig. 
2.5C). The acceptor phages DMS3macrIF1 (Fig. 2.3G) and DMS3macrIF4 (Fig. 2.3H) replicated 
robustly from input MOIs that are unsuccessful in the absence of an AcrIF1 donor phage (Fig. 
2.3G-H, see “IE3” and “buffer”). The presence of AcrIF1 donor phages had a mildly protective 
effect on the DMS3macrIE3 acceptor phage (Fig. 2.3I), though it was not able to reach high titers. 
Notably, the acceptor phage output from these experiments remain as sensitive to CRISPR-Cas 
targeting by the 5sp host as the original input phages, demonstrating escape mutations do not 
arise under these conditions (Fig. 2.4D-G). Additionally, any potential lysogens formed by the 
donor phage in this experiment would not have amplified the replicating phage, as these 
lysogens are resistant to superinfection (Fig. 2.5D). These data demonstrate that the 
determinant of phage replicative success is the concentration of Acr proteins reached in single 
cells, which is achievable by Acr production from independent phage genomes (Fig. 2.3J).  
 
Lysogeny requires Acr proteins contributed by transient intracellular genomes 
All phages encoding Acr proteins that infect P. aeruginosa are naturally temperate, and can 
form lysogens by integrating into the bacterial genome. We therefore measured the impact of 
CRISPR and Acr proteins on lysogeny establishment during a single round of infection. While 
previous experiments examined cumulative phage replication in the lytic cycle over many hours, 
assaying lysogen formation over a short time frame is ideal for understanding the initial events 
that determine phage genome survival or cleavage. Additionally, lysogeny provides a direct 
readout for phage genome survival (i.e. a cell with an integrated prophage), while in lytic 
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replication, phage survival leads to a dead cell that cannot be recovered. For these 
experiments, we selected the weak AcrIF4 protein as it provided the largest dynamic range of 
inefficiency in a single round of infection. 
 
We generated derivatives of DMS3macrIF4 and DMS3macrIE3 marked with a gentamicin resistance 
cassette at the end of the genome, replacing a nonessential gene, gp52. This allowed the 
independent titration of two distinct replication-competent phage populations and the selection 
and analysis of stable lysogens after the experiment. These phages were used to infect 
∆CRISPR cells (0sp) for a time span less than a single round of infection (50 minutes, data not 
shown), and the number of gentamicin resistant lysogens was assessed. In the absence of 
CRISPR selection, a linear increase in the number of lysogens with increasing MOI was 
observed, over ~4 orders of magnitude (Figs. 2.6A-B, circles). In the presence of spacers 
targeting DMS3m (5sp), CRISPR immunity reduced the number of lysogen forming units (LFUs) 
for the weak acr phage DMS3macrIF4 (Fig. 2.6A, triangles). DMS3macrIF4 demonstrated 
concentration dependence for successful lysogeny, with efficiency of lysogeny (EOL) values 
below or at the limit of detection for lower MOIs, increasing to EOL = 0.01 at higher MOIs (Fig. 
2.6C). Phage DMS3macrIE3 formed no lysogens at all input concentrations tested, demonstrating 
that Acr-mediated immune suppression is required to establish lysogeny (Figs. 2.6B, 2.6D). 
  
We hypothesized that phage concentration dependence for CRISPR neutralization during 
lysogeny could also be explained by phage cooperation, and that below-threshold 
concentrations of DMS3macrIF4 gp52::gent could be rescued by the addition of wild-type (replication 
competent) Acr donor phages in trans. To test this hypothesis, we infected the 5sp strain with a 
mixture of 103 LFU marked acceptor phage and 107 PFU of unmarked Acr donor phages, and 
measured the EOL of the acceptor phage. The EOL of the acceptor phage DMS3macrIF4 gp52::gent 
increased by 2 orders of magnitude with Acr donor phage DMS3macrIF1, and by 1 order of 
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magnitude with the DMS3macrIF4 donor phage (Fig. 2.6E). The addition of Acr donor phages 
DMS3macrIE3, or an escaper phage DMS3macrIE3* had no effect on the EOL of the acceptor 
phage, demonstrating that the donor phage must be an Acr-producer. A marked acceptor phage 
lacking an acrIF gene (DMS3macrIE3 gp52::gent) only established rare lysogens in the presence of 
the AcrIF1 donor phage (Fig. 2.6F).  
 
To determine the specific mechanism of anti-CRISPR donation leading to survival of the 
acceptor phages, we used the resulting lysogens as a genetic record of infection success for 
both the marked acceptor phage and the unmarked donor phage (Fig. 2.6G). This family of Mu-
like phages integrates randomly into the host genome, allowing for the formation of strains with 
multiple prophages 37. We assayed the lysogens resulting from the experiment described above 
(Fig. 2.6E-F) for the presence of the donor prophage genome in addition to the acceptor 
prophage. All resulting DMS3macrIF4 gp52::gent lysogens (n=48) possessed only the marked 
acceptor prophage, with none possessing the Acr donor prophage (Fig. 2.7A-B). Furthermore, 
the DMS3macrIF4 gp52::gent acceptor phages induced from the lysogens that formed only in the 
presence of Acr donor phages remained sensitive to CRISPR-Cas targeting, indicating these 
lysogens did not arise due to phage protospacer mutation (Fig. 2.7B). Double lysogens only 
emerged when the marked acrIE3 phage was used as an acceptor phage, which would be 
incapable of maintaining lysogeny alone due to CRISPR-Cas self-targeting (Fig. 2.6F). These 
results demonstrate that the transient presence (i.e. no lysogeny) of an Acr donor phage 
genome in a cell was sufficient to generate enough Acr protein to protect the marked acceptor 
phage, leading to the establishment of lysogens that would not exist if not for the Acr donor (Fig. 
2.6E, compare “Buffer” to “IF1”). Collectively, these data demonstrate that the production of Acr 
proteins from a phage genome prior to its cleavage generates an immunosuppressed cell that 
can be successfully parasitized by another phage upon re- or co-infection(s).  
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Cas9 inhibitors require bacteriophage cooperation  
The intrinsic inefficiency of stoichiometric inhibitors is likely due to the requirement for the rapid 
synthesis of a high concentration of inhibitors before phage genome cleavage. To determine 
whether this model generally applies to other stoichiometric inhibitors of bacterial immunity, we 
engineered a P. aeruginosa strain to express the Cas9 protein from Streptococcus pyogenes 
(SpyCas9) and a DMS3m phage to express a previously identified Cas9 inhibitor, AcrIIA4 18,33. 
With this entirely heterologous system, we again observed inefficiency for a phage relying on an 
Acr protein. Spot-titration of phage lysates on a strain expressing a single guide RNA (sgRNA) 
targeting DMS3m decreased the titer of DMS3macrIE3 by >3 orders of magnitude, while 
DMS3macrIIA4 was protected (Fig. 2.8A). However, EOP quantification again revealed that 
relying on an Acr protein for replication is imperfect, with an EOP = 0.4 (Fig. 2.8B). In lytic 
replication infection experiments, DMS3macrIIA4 displayed concentration-dependent bacterial 
lysis in the presence of CRISPR targeting (Fig. 2.8C), while DMS3macrIE3 did not affect bacterial 
growth (Fig. 2.8D). The replication of DMS3macrIIA4 was not due to protospacer mutation leading 
to phage escape because the output phage population displayed the same EOP as the input 
(Fig. 2.4H-I). In the absence of CRISPR-Cas targeting, however, both phages killed their hosts 
at all phage concentrations tested (Fig. 2.8E-F).  
 
To determine whether this concentration dependence for Cas9 inhibition was also a result of 
insufficient intracellular Acr dose, a non-replicative hybrid DMS3macrIIA4 phage was generated 
and used as an Acr donor during infection. Indeed, increased delivery of AcrIIA4 to cells 
enhanced replication of the wild-type DMS3macrIIA4 acceptor phage by 4 orders of magnitude 
(Fig. 2.8G), demonstrating phage cooperation neutralizes CRISPR-Cas9. AcrIIA4 donation was 
able to slightly rescue an acceptor phage without a II-A Acr, DMS3macrIE3 (Fig. 2.8H), however 
this phage was unable to replicate to high titers. Furthermore, the effect of an AcrIIA4 donor 
rescuing either DMS3macrIIA4 or DMS3macrIE3 was not due to mutational escape of the acceptor 
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phage (Fig. 2.4J-L), demonstrating these phages had survived solely due to the 
immunosuppressive effect of AcrIIA4 donation (Fig. 2.8I). Collectively, these data demonstrate 
that phage-phage cooperation via cellular immunosuppression is a broadly useful strategy to 
overcome bacterial immunity.  
 
DISCUSSION 
Here we demonstrate that the necessary intracellular concentration of an anti-CRISPR protein 
to achieve inactivation of CRISPR-Cas immunity depends on the relative strengths of both the 
inhibitor and CRISPR immunity, which dictates the number of infecting viruses required in the 
population. We conclude that a single cell can become immunosuppressed by Acr protein 
contributions from independent infection events. In the absence of viral replication, these 
infection events serve to contribute to the inactivation of cellular immunity, thus enhancing the 
probability of successful infection events in the future. We expect that cooperation of this sort is 
necessary when the immune process acts rapidly and irreversibly on the infecting viral genome, 
as CRISPR-Cas immunity does. 
 
Anti-CRISPR deployment and successful CRISPR-Cas inactivation requires a critical 
concentration of phage in the population to allow replication in the lytic or lysogenic cycle. We 
used three distinct genetic strategies to monitor phage-phage cooperation within an otherwise 
clonal population, allowing the independent titration and tracking of isogenic phages: i) non-
replicative Acr donor phages, ii) marked and unmarked phages to follow the fate of only one 
phage, and iii) the prophage status of lysogens, as a genetic record of phage success. In the 
presence of non-replicative Acr donor phages, we observed the successful lytic amplification of 
a low-dose of wild-type phages, otherwise destined for replication failure (Fig. 2.3G-H). This 
provided an explanation for the observed phage inefficiencies during plaque assays (Fig. 2.1A-
B) and population concentration thresholds in liquid infections (Fig. 2.3A-B). Next, the 
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acquisition of a marked prophage was monitored in the presence of wild-type Acr-donor phages. 
AcrIF proteins provided in trans caused cellular immunosuppression, enabling the formation of 
lysogens that were not established in their absence (Fig. 2.6E-F). The presence of only a 
single, marked prophage in the bacterial genome demonstrates that the donor phage neither 
entered the lytic cycle (this would kill the cell), nor lysogenized (prophage would be integrated), 
but had been present in the cell transiently.  
 
The key result here is the observation that phages can remodel their host cell, even in the 
absence of a replicating or integrated genome. It has long been known that integrated 
prophages modulate host phenotypes via gene expression, including superinfection exclusion, 
toxin production, and the production of Acr proteins 15,37-40. Furthermore, the Imm protein 
produced by the lytic phage T4 prevents other phages in the environment from infecting the cell 
that one phage is currently replicating within 41. This has been attributed to preventing 
sequential infections and the disruption of the carefully timed phage replication cycle. In contrast 
to these examples, we propose a new model of phage-induced host remodeling, whereby a 
transient, unsuccessful infection produces proteins that inactivate defense, enabling future 
infections.  
 
Consistent with our observations of viral cooperation, beneficial virus-virus interactions in both 
eukaryotic and prokaryotic systems have been previously observed. Broadly, these phenomena 
can be separated into 2 categories: i) cooperative interactions between distinct viral genotypes 
and ii) group behaviors manifested in clonal viral populations: i) Similar to Acr proteins 
functioning as a public good, genetically distinct viruses can share protein products during 
coinfection 42, even bypassing deleterious mutations in cis via functional complementation in 
trans 43-45. Additionally, the direct exchange of viral genetic material can also increase viral 
fitness. The mosaic nature of phage genomes 46-48 and the high abundance of chimeric viruses 
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in nature highlights the importance of coinfection and genetic exchange in viral evolution 49-51. In 
fact, CRISPR-targeted phages can evade CRISPR-Cas immunity via homologous 
recombination with genetically distinct phages, disrupting protospacers 52,53. ii) Group behaviors 
manifesting in clonal populations of virus is less frequently reported, likely because they leave 
no genetic signature. However, the lambda lytic/lysogeny switch is a famous example of phage 
group behavior: during lambda phage co-infection, high concentrations of the CII protein product 
derived from multiple infecting clones drives the cooperative decision to enter lysogeny 54-56. In 
more recent literature, the discovery of the widespread arbitrium system as the first phage-
phage communication mechanism demonstrates the potential of phages to act as a group and 
manifest cooperative behaviors 57. The immunosuppressive mechanism of anti-CRISPR 
function further exemplifies cooperation within clonal populations of phages, which may occur 
more often than was previously appreciated. The distinct aspect here is the altruistic nature of 
immunosuppression: to neutralize CRISPR-Cas immunity, many infections must fail such that a 
few can succeed. To our knowledge this is the first documented example of true viral altruism, 
which is evolutionary beneficial only through kin selection.  
 
A distinct, but notable observation from this work is that not all Acr proteins operate at 
equivalent strengths. However, encoding even a weak inhibitor (e.g. AcrIF4) still provides a 
significant advantage to the phage, compared to lacking them entirely (Fig. 2.1B). We show that 
AcrIF4 binds the Csy complex with affinities that are orders of magnitude weaker (Fig. 2.1C) 
than Acr proteins like AcrIF1 and AcrIF2 25. We selected AcrIF1 as a model strong Acr protein 
because of its comparable mechanism of action to AcrIF4 (i.e. Csy complex binding), and 
consider it representative of other strong Acr proteins (AcrIF2, F3, F6, F7), based on EOP data. 
Going forward, we speculate that the strongest Acr proteins would be enzymatic in nature, 
allowing rapid and efficient inactivation of CRISPR complexes in a sub-stoichiometric manner, 
although no such Acr mechanism has been discovered. While not an enzyme, the recent 
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demonstration of the AcrIIC3 protein inactivating two Cas9 proteins at the same time would 
likely be a more efficient path towards CRISPR neutralization 34. It is also interesting to consider 
individual bacterial strains that encode multiple CRIPSR-Cas system subtypes 58-60, all which 
must be neutralized in order for a targeted phage to replicate. A dual-activity inhibitor is likely at 
a specific disadvantage in this scenario, as one protein would be tasked with inhibiting Cas 
proteins produced by two different systems. This may in part explain why DMS3m-like 
Pseudomonas phages often encode dedicated Type I-E and Type I-F Acrs in the same Acr 
locus 15,17, instead of employing dual I-F and I-E inhibitors such as AcrIF6 16. Although encoding 
multiple Acrs comes with the burden of more genetic cargo in a phage’s genome, this strategy 
could be advantageous on a biochemical level when infecting a bacterial strain with multiple 
CRISPR-Cas subtypes. 
 
The challenge of neutralizing a pre-expressed CRISPR-Cas system likely explains why 
stoichiometric inhibitors like Acr proteins are imperfect, and phages relying on them are partially 
targeted by CRISPR. The sacrificial, population-level aspect of CRISPR inhibition is reminiscent 
of the manifestations of CRISPR adaptation in populations of bacterial cells. The majority of 
infected naïve host cells die, before a clone with a new spacer emerges 2,61. In the case of anti-
immunity, many phages die in order to inhibit CRISPR on a single cell level, and this must 
happen at a sufficient frequency within a community for phage to prevail. We suspect that this 
mechanism of cellular immunosuppression and inter-parasite cooperation may have parallels in 
other host-pathogen interactions, where concentration dependence manifests at predictable 
levels due the strengths of immune and anti-immune processes.   
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MATERIALS AND METHODS 
 
Microbes 
Pseudomonas aeruginosa strains (UCBPP-PA14 and PAO1) and Escherichia coli strains 
(DH5α, for plasmid maintenance) were cultured on lysogeny broth (LB) agar or liquid media at 
37 °C. LB was supplemented with gentamicin (50 µg/mL for P. aeruginosa, 30 µg/mL for E. coli) 
to maintain the pHERD30T plasmid or carbenicillin (250 µg/mL for P. aeruginosa, 100 µg/mL for 
E. coli) to maintain pHERD20T or pMMB67HE. To maintain pHERD30T and pMMB67HE in the 
same strain of P. aeruginosa, double selection of 30 µg/mL gentamicin and 100 µg/mL 
carbenicillin was employed. In all P. aeruginosa experiments, expression from pHERD20/30T 
was induced with 0.1% arabinose and expression from pMMB67HE was induced with 1mM 
Isopropyl ß-D-1-thiogalactopyranoside (IPTG).  Escherichia coli strains BL21 (DE3) were grown 
in LB broth supplemented with ampicillin (100 µg/mL) to maintain pAcrIF4, or with ampicillin 
(100 µg/mL) and kanamycin (50 µg/mL) to maintain pCsy and pCRISPR together.  
 
Phages 
Pseudomonas aeruginosa DMS3m-like phages (JBD30, MP29, JBD88a, JBD24, LPB1, DMS3m 
and DMS3m derivatives) were amplified on PA14 ∆CRISPR or PAO1 and stored in SM buffer at 
4 °C. 
 
Construction of PA14 crRNA overexpression strains 
PA14 CRISPR2 spacer-17 or CRISPR2 spacer-20 sequences flanked by PA14 Type I-F direct 
repeats were ordered as complementary ssDNA oligos (IDT), annealed, and ligated into the 
NcoI/HindIII site in pHERD30T to make pAB02 and pAB03, respectively.   These constructs 
were transformed into PA14 WT, and expression induced with 0.1% arabinose.  
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Construction of PAO1::SpyCas9 expression strain 
SpyCas9 expressed from the PLAC promoter of pUC18T-mini-Tn7T-Gm (pBAO95) was 
integrated into the P. aeruginosa strain PAO1 chromosome by electroporation and Flp-mediated 
marker excision as previously described 62. To generate the heterologous Type II-A PAO1 strain 
the PAO1-attTn7::pUC18T-miniTn7T-PLAC-SpyCas9 strain was transformed with pMMB67HE-
PLAC-sgRNA (pBAO72) by electroporation. In all experiments with this strain, SpyCas9 and the 
sgRNA were induced with 1mM IPTG.  
 
Construction of recombinant DMS3macr phages 
DMS3macrIF1 was generated previously 15 by infecting cells containing a recombination plasmid 
bearing JBD30 genes 34-38 (the anti-CRISPR locus with large flanking regions). JBD30 
naturally carries acrIF1 and has high genetic similarity to DMS3macrIE3, permitting for the 
selection of recombinant DMS3m phages that acquired acrIF1. To generate the extended panel 
of DMS3macr phages in this work, recombination cassettes were generated with regions from up 
and downstream the anti-CRISPR gene from JBD30 and these fragments were assembled to 
flank the acr gene of interest on pHERD20T or pHERD30T (see Table 2.1 for acr gene sources, 
Table 2.2 for recombination plasmids) using Gibson assembly methods. In the case of AcrIF5, 
AcrIF6, and AcrIIA4 recombination cassettes, a ribosomal binding site was introduced between 
the acr and the downstream gene aca1 to ensure proper expression of the aca1 gene.  
Recombinant phages were generated by infecting cells bearing these recombination substrates. 
DMS3macr phages were screened for their ability to resist CRISPR targeting, and the insertion of 
the anti-CRISPR gene was confirmed by PCR. Virulent derivatives of DMS3macr phages were 
constructed by deleting gp1 (C repressor) using materials and methods previously generated6.  
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Construction of DMS3macr gp52::gent phages 
A recombination substrate (pAB45) with a gentamicin resistance cassette flanked by homology 
arms matching the DMS3m genome up and downstream of gp52 (450 bp and 260 bp, 
respectively) was assembled into pHERD20T using Gibson assembly. This recombination 
cassette was transformed into PA14 ∆CRISPR lysogenized with either DMS3macrIE3 or 
DMS3macrIF4.These transformed lysogens were grown under gentamicin selection for 16 hours, 
then sub-cultured 1:100 into LB with gentamicin and 0.2 µg/mL mitomycin C to induce the 
DMS3macr prophage. Supernatants were harvested after 24 hours of induction, and used to 
infect PA14 ∆CRISPR in liquid culture for 24 hours. These cells were then plated on gentamicin 
plates to select for cells that had acquired a prophage bearing the gentamicin resistance 
cassette, and gentamicin resistant lysogens were then re-induced with 0.2 µg/mL mitomycin C 
to recover the recombinant phage.   
 
Construction of DMS3macr gp1-JBD30  Hybridacr phages 
DMS3macrIE3 and JBD30acrIE3 were used to co-infect PA14 ∆CRISPR and the infected cells were 
mixed with molten top agar and poured onto solid plates. After 24 hours of growth at 30 °C, the 
phages were harvested by flooding the plate with SM buffer and collecting and clarifying the 
supernatant. Phages were then used to infect PA14 ∆CRISPR expressing the DMS3m C 
repressor from pHERD30T (pAB80), and the infections were mixed with molten top agar and 
poured onto solid plates. After 24 hours of growth at 30 ºC, individual plaques with DMS3m 
morphology were picked, purified 3x by passage in PA14 ∆CRISPR and screened as shown in 
Fig. 2.5B. The acrIF1 gene was then knocked in to this hybrid phage using methods described 
above to generate DMS3macrIF1 gp1-JBD30. 
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Plaque forming unit quantification 
Phage plaque forming units (PFU) were quantified by mixing 10 µl of phage with 150 µl of an 
overnight culture of host bacteria. The infection mixture was incubated at 37 ºC for 10 minutes 
to promote phage adsorption, then mixed with 3 mL molten top agar and spread on an LB agar 
plate supplemented with 10 mM MgSO4. After 16 hours of growth 30 ºC, PFUs were quantified.  
 
Phage titering  
A bacterial lawn was generated by spreading 3 mL of top agar seeded with 150 µl of host 
bacteria on a LB agar plate supplemented with 10 mM MgSO4. 3 µl of phage serially diluted in 
SM buffer was then spotted onto the lawn, and incubated at 30 ºC for 16 hours.  
 
Liquid culture phage infections 
A P. aeruginosa overnight culture was diluted 1:100 in LB supplemented with 10 mM MgSO4, 
required antibiotics and inducer. 140 µl of diluted bacteria were then infected with 10 µl of phage 
diluted in SM buffer in a 96 well Costar plate. These infections proceeded for 24 hours in a 
Synergy H1 microplate reader (BioTek, using Gen5 software) at 37 ºC with continuous shaking. 
After 24 hours, phage was extracted by treating each sample with chloroform followed by 
centrifugation at 21,000 x g for 2 minutes.  
 
Prophage acquisition and lysogen analysis  
Overnight cultures of PA14 were subcultured at 1:100 for ~3 hours (OD600nm = 0.3) in LB 
supplemented with 10 mM MgSO4. 1 mL of cells was infected with 10 µl DMS3macr gp52::gent and 
incubated for 50 minutes at 37 ºC, shaking at 100 rpm. The sample was then treated with a 10% 
volume of 10X gentamicin, spun down at 8,000xg, and resuspended in 200 µl of LB with 50 
µg/mL gentamicin. 100 µl of sample was then plated (after further dilution, if required) on 
gentamicin selection plates and incubated at 37 ºC. To analyze the lysogens, the resulting 
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colonies were grown for 16 hours in LB + 10 mM MgSO4 (no selection), the supernatants 
harvested, and serial dilutions spotted onto lawns of non-targeting PA14 (0sp) or PA14 with 5 
targeting spacers (5sp). Crude genomic DNA for PCR analysis was harvested from the 
lysogens by boiling 10 µl of culture in 0.02% SDS for 10 minutes.  
 
Lysogen PCR 
PCR amplification of 2 µl of crude genomic DNA harvested from lysogens was used to screen 
for the presence of DMS3m-gp52 and the gent cassette using MyTaq (Bioline) polymerase with 
MyTaq GC buffer under standard conditions.  
 
Csy complex purification 
Csy genes and a synthetic CRISPR array were co-expressed on separate vectors (pCsy, 
pCRISPR) in E. coli BL21 (DE3) cells as previously described 28. Expression was induced with 
0.5 mM Isopropyl ß-D-1-thiogalactopyranoside (IPTG) at OD600 ~ 0.5. Cells were incubated 
overnight at 16°C, then pelleted by centrifugation (5,000 × g for 15 min at 4 °C), and 
resuspended in lysis buffer [50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) pH 7.5, 300 mM potassium chloride, 5% glycerol, 1 mM Tris(2- carboxyethyl) 
phosphine hydrochloride (TCEP), 1× protease inhibitor mixture (Thermo Scientific)]. Pellets 
were sonicated on ice for 3 × 2.5 min (1 s on, 3 s off), and then the lysate was clarified by 
centrifugation at 22,000 × g for 30 min at 4 °C. The Csy complex self-assembles in vivo, and the 
intact complex was affinity-purified over NiNTA Superflow resin (Qiagen) using 6xhis tags on 
Cas7f. Protein was eluted with lysis buffer supplemented with 300 mM imidazole and then 
concentrated (Corning Spin-X concentrators) at 4 °C before further purification over a Superdex 
200 size-exclusion column (GE Healthcare) in 20 mM Hepes pH 7.5, 100 mM KCl, 5% glycerol, 
and 1 mM TCEP. 
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AcrIF4 purification 
Gene 37 from phage JBD26 (AcrIF4) was cloned into a p15TV-L vector with N-terminal His6 
tags (pAcrIF4) and expressed in E. coli BL21 (DE3) cells. Expression was induced with 0.5 mM 
IPTG at OD600 ~ 0.5. Cells were incubated overnight at 16°C, then pelleted by centrifugation 
(5,000 × g for 15 min at 4 °C), and resuspended in lysis buffer containing 50 mM Tris, pH 7.5, 
300 mM NaCl, 5% glycerol, 0.5x protease inhibitor cocktail (Thermo Scientific) and 1 mM TCEP. 
Cells were lysed by sonication and lysate was clarified by centrifugation as described above. 
AcrIF4 protein was affinity-purified over NiNTA Superflow resin (Qiagen) and eluted in lysis 
buffer supplemented with 300 mM imidazole, then concentrated (Corning Spin-X concentrators) 
at 4 °C before further purification over a Superdex 75 size-exclusion column (GE Healthcare) in 
20 mM Tris, pH 7.5, 250 mM NaCl, 5% glycerol, 1 mM TCEP. 
 
Surface plasmon resonance 
Purified Csy complex was covalently immobilized by amine coupling to the surface of a 
carboxymethyldextran-modified (CM5) sensor chip (GE Healthcare). Purified 6his-tagged AcrIF4 
was injected into the buffer flow in increasing concentrations (1.85 nM, 55.6 nM, 167 nM, 500 
nM, 1.5 uM), and Csy complex-AcrIF4 binding events were recorded in real time. Experiments 
were conducted at 37°C, in 20 mM HEPES pH 7.5, 100 mM KCl, 1mM TCEP, 0.005% Tween.  
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
All numerical data, with the exception of the surface plasmon resonance (SPR) data, were analyzed 
and plotted using GraphPad Prism 6.0 software.  The SPR data were analyzed and plotted using 
Biocore evaluation software (GE). Below, we provide the details of the number of biological 
replicates as well as data quantification and presentation for the experimental methods utilized in 
this manuscript.  
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Efficiency of plaquing (Fig. 2.1A-B, Fig. 2.8B, Fig. 2.4A-L) 
Efficiency of plaquing (EOP) was calculated as the ratio of the number of plaque forming units 
(PFUs) that formed on a targeting (+CRISPR, +sgRNA) strain of bacteria divided by the number of 
PFUs that formed on a non-targeting (∆CRISPR, vector) strain. Each PFU measurement was 
performed in biological triplicate. The EOP data in Fig. 2.1A-B and Fig. 2.8B are displayed as the 
mean EOP +/- standard deviation (error bars) whereas the EOP data in Fig. 2.4A-L are displayed as 
individual replicate values overlayed with the mean EOP value +/- standard deviation. 
 
Bacterial growth curves (Fig. 2.3A-F, Fig. 2.8C-F) 
OD600nm values were measured in biological triplicate for each experimental condition over a period 
of 12 hours, and the data displayed as the mean OD600nm as a function of time (hours) +/- standard 
deviation (error bars).  
 
Quantification of phage lytic replication (Fig. 2.3G-I, Fig. 2.8G-H, Fig. 2.5C) 
Phage infections were performed in biological triplicate, and the phages harvested from each 
infection were quantified as plaque forming units (PFUs) on a non-targeting (∆CRISPR, vector) 
strain. Values are displayed as the mean number of PFUs from the 3 experimental replicates, +/- 
standard deviation (error bars).  
 
Quantification of phage lysogeny (Fig.  2.6A-B) 
Phage lysogeny was measured as the number of lysogen forming units (LFUs) that formed under a 
given experimental condition. In our experimental setup, each sample was diluted at least 2-fold 
before quantification, meaning that the limit of detection (LoD) of this assay is 2 LFUs. Phage 
lysogeny experiments were performed in biological triplicate, and each replicate value is displayed.   
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Efficiency of lysogeny (Fig. 2.6C-F) 
Efficiency of lysogeny (EOL) was calculated as ratio of the number of lysogen forming units (LFUs) 
that form under the targeting condition (5sp) divided by the number of LFUs that form under the non-
targeting condition (0sp). Phage lysogeny experiments were performed in biological triplicate, and 
EOL is displayed as mean EOL +/- standard deviation (error bars).  
 
Analysis of AcrIF4 binding kinetics (Fig. 2.1C, Fig. 2.2) 
Data were fit with a model describing Langmuir binding (i.e. 1:1 binding between free analyte 
and immobilized ligand). Plotted residual data points scattered around zero and were <10% of 
Rmax, indicating good model fit. Kinetic rate constants were extracted from this curve fit using 
Biacore evaluation software (GE). Parameter significance was evaluated by assessing standard 
error (SE)/T-value (T-value = parameter value/standard error). This value provides a measure of 
how sensitive the model fit is to changes in the parameter value; high SE/low T-value indicates 
poor significance. SEs for ka and kd were both >21-fold lower than T-values, indicating good 
significance.  
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Figure 2.1. Anti-CRISPRs are imperfect CRISPR-Cas inhibitors  
(A) Efficiency of plaquing (EOP) of 5 related phages bearing distinct acrIF genes (JBD30acrIF1, 
MP29acrIF2, JBD88aacrIF3, JBD24acrIF4, LPB1acrIF7) on Pseudomonas aeruginosa strain PA14. 
Plaque forming units (PFUs) were quantified on wild-type PA14 with 1-2 natural targeting 
spacers (WT + pEmpty) or on PA14 overexpressing 1 targeting spacer (WT + pSp1), then 
normalized to the number of PFUs measured on a non-targeting PA14 derivative (0sp). Data 
are represented as the mean of 3 biological replicates +/- SD. 
(B) EOP of isogenic DMS3macr phages with acrIF1-7 or acrIE3 in the DMS3m acr locus. EOP 
was calculated as PFU counts measured on WT PA14 with 1 targeting spacer (1sp) or a 
laboratory evolved PA14 derivative with 5 targeting spacers (5sp) normalized to PFU counts 
measured on non-targeting PA14 (0sp). Data are represented as the mean of 3 biological 
replicates +/- SD. ND, not detectable. 
(C) Plot of association (ka) and dissociation (kd) rates for AcrIF1 (data adapted from Chowdhury 
et al. 2017) and AcrIF4 binding the PA14 Csy complex. AcrIF1 rate constants: ka = 5 x 104 
(1/Ms), kd = 2 x 10-7 (1/s), KD = 3 x 10-11 M. AcrIF4 rate constants: ka = 1 x 103 (1/Ms), kd = 5 x 10-
4 (1/s), KD = 4 x 10-7 (M). See Fig. 2.2 for AcrIF4 SPR sensogram.  
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Figure 2.2. Sensogram of AcrIF4 binding the Csy complex, Related to Fig. 2.1C 
Sensogram showing real-time binding of increasing concentrations of free AcrIF4 (1.85 nM, 55.6 
nM, 167 nM, 500 nM, 1.5 µM) to immobilized Csy complex. A model describing Langmuir 
binding (black line) was fit to the data to calculate binding constants (ka, kd, and KD; boxed 
inset).  
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Figure 2.3. Anti-CRISPR success requires cooperative infections during lytic growth  
(A-F) 12-hr growth curves of P. aeruginosa strain PA14 with 5 targeting spacers (+CRISPR) 
infected with virulent variants of DMS3macrIF1 (A), DMS3macrIF4 (B), or DMS3macrIE3 (C) at 
multiplicities of infection (MOI) increasing in 10-fold steps from 2 × 10-5 to 2 × 101 (rainbow 
colors) or uninfected (black). As a control, P. aeruginosa strain PA14 with no CRISPR-Cas 
function (∆CRISPR) was infected with DMS3macrIF1 (D), DMS3macrIF4 (E), or DMS3macrIE3 (F) 
under the same conditions. Colors correspond to the MOI legend and growth curves. OD600nm is 
represented as the mean of 3 biological replicates ± SD (vertical lines). ND, not detectable. 
 (G-I) Replication of virulent DMS3macrIF1  (G), DMS3macrIF4 (H), or DMS3macrIE3 (I) (acceptor 
phages) in the presence of 106 PFU (MOI 0.2) hybrid phage (donor) in PA14 with 5 targeting 
spacers (5sp) expressing the JBD30 C repressor. Phages were harvested after 24 hr of co-
culture and DMS3macr phage PFUs were quantified on PA14 0sp expressing the JBD30 C 
repressor. Phage output is represented as the mean of 3 biological replicates ± SD. ND, not 
detectable.  
(J) Schematic of the experimental design in G-I, where a high MOI of non-replicative “donor” 
phages is used to rescue a low MOI infection of wild-type “acceptor” phages.  
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Figure 2.4. Output phages from liquid growth experiments remain CRISPR sensitive, 
Related to Fig. 2.3 and Fig. 2.8  
(A-C) Efficiency of plaquing (EOP) of the original stocks of virulent DMS3macr  (input) on PA14 
5sp compared to EOP of DMS3macr harvested from high MOI infections in Figure 2A-C (MOI 
2x10-2, MOI 2x10-1 output for DMS3macrIF1 and MOI 2 and MOI 20 output for DMS3macrIF4 and 
DMS3macrIE3).  
(D-F) EOP of acceptor output phages that amplified in the presence of AcrIF1 donor phages 
from Figure 2D-F on PA14 5sp compared to the original stock of virulent DMS3macr (input). 
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Figure 2.5. Generating and validating Hybridacr phages, Related to Fig 2.3 and Fig. 2.8 
 (A) 10-fold serial dilutions of hybrid DMS3macrIE3 gp1-JBD30 plated on lawns of non-targeting (0sp) 
Pseudomonas aeruginosa PA14 expressing the DMS3m C repressor (gp1-DMS3m), the JBD30 
C repressor (gp1-JBD30), or a crRNA which uniquely targets JBD30 (2sp17) outside of the 
immunity region. 
(B) 10-fold serial dilutions of DMS3macrIE3 and JBD30acrIF1 spotted on lawns of non-targeting 
(0sp) Pseudomonas aeruginosa PA14 expressing the DMS3m C repressor (gp1-DMS3m), the 
JBD30 C repressor (gp1-JBD30), or a vector control. 
(C) Hybrid phage (HybridacrIF1 or HybridacrIE3) harvested from infections of PA14 5sp expressing 
the JBD30 C repressor from experiments shown in Figure 2G-I. Hybrid PFUs were quantified on 
the 0sp PA14 strain. Data are represented as the mean of 3 biological replicates +/- SD. 
(D) 10-fold serial dilutions of JBD30acrIF1 or virulent DMS3macrIE3 spotted on lawns of PA14 ∆csy3 
or PA14 ∆csy3 lysogenized with HybridacrIE3 or HybridacrIF1. Despite being heteroimmune with 
respect to JBD30, the DMS3m phage is unable to replicate well on this lysogens due to other 
superinfection exclusion properties of DMS3m.  
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Figure 2.6. Immunosuppression facilitates acquisition of a marked prophage 
(A,B) Acquisition of a marked DMS3macrIF4 gp52::gent (A) or DMS3macrIE3 gp52::gent (B) prophage by 
PA14 with 0 spacers (0sp, circles) or 5 targeting spacers (5sp, triangles). This experiment was 
performed in biological triplicate, and individual replicate values are displayed. LoD, limit of 
detection. 
(C,D) Efficiency of lysogeny (EOL) of DMS3macrIF4 gp52::gent (A) and DMS3macrIE3 gp52::gent (B) in the 
presence of CRISPR targeting. EOL was calculated by dividing the output lysogens forming 
units (LFUs) from the strain with 5 targeting spacers (5sp) to the number of LFUs in PA14 with 0 
targeting spacers (0sp). Data are represented as the mean of 3 biological replicates ± SD. ND, 
not detectable.  
(E,F) EOL of 103 LFUs of DMS3macrIF4 gp52::gent (E) and DMS3macrIE3 gp52::gent (F) in the presence of 
107 PFU of the indicated DMS3macr phage. Data are represented as the mean of 3 biological 
replicates ± SD. ND, not detectable. See Figure S4 for analysis of lysogen prophage content. 
(G) Schematic of the experimental design in E-F, where a high MOI of wild-type “donor” phages 
is used to rescue a low MOI infection of marked “acceptor” phages.  
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Figure 2.7. Prophage content of immunosuppressed lysogens, Related to Figure 2.6E-F  
(A) PCR of genomic DNA harvested from overnight cultures of lysogens from Figure 3E (1-48) 
and 3F (49-51) amplified with primers targeting gp52-DMS3m (top) or the gentamicin resistance 
cassette used to replace gp52 in DMS3macr gp52::gent derivatives (bottom). 
(B) 10-fold serial dilutions of supernatant harvested from overnight cultures of lysogens from 
Figure 3E (1-48) and 3F (49-51), spotted on a non-targeting (0sp) strain of PA14 and the 5 
spacer (5sp) targeting strain of PA14. A faint clearing corresponds to induction of the gentamicin 
	 77 
 
Figure 2.8. Cas9 anti-CRISPR AcrIIA4 requires cooperative infection to neutralize Type II-
A CRISPR immunity   
(A) 10-fold serial dilutions of DMS3macrIE3 or DMS3macrIIA4 plated on a lawn of Pseudomonas 
aeruginosa strain PAO1 expressing Streptococcus pyogenes Type II-A Cas9 (PAO1::SpyCas9) 
and single guide RNA (+ sgRNA) or non-targeting control (+ vector). 
(B) Efficiency of plaquing of DMS3macrIIA4 and DMS3macrIE3 was calculated by normalizing PFU 
counts on a targeting strain of PAO1::SpyCas9 ( +sgRNA) to PFU counts on a non-targeting 
strain of PAO1::SpyCas9 (+vector). Data are represented as the mean of 3 biological replicates 
+/- SD. ND, not detectable. 
(C-F) 12-hr growth curves of P. aeruginosa strain PAO1::SpyCas9 expressing a targeting 
sgRNA (+sgRNA) infected with virulent DMS3macrIIA4 (C) or DMS3macrIE3 (D) at multiplicities of 
infection (MOI, rainbow colors) from 2 × 10-5 to 2 × 10-2. Growth curves of uninfected cells are 
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shown in black. As a control, a non-targeting strain of PA01::SpyCas9 (+vector) was infected 
with DMS3macrIIA4 (E) or DMS3macrIE3 (F) under the same conditions. OD600nm values are 
represented as the mean of 3 biological replicates ± SD (vertical lines). 
 (G-H) Replication of virulent DMS3macrIIA4 (G) or DMS3macrIE3 (H) (acceptor phage) in the 
presence of 107 PFU (MOI 2) hybrid phage (donor) in PAO1::SpyCas9 + sgRNA expressing the 
JBD30 C repressor. Phages were harvested after 24 hr and DMS3macr phage PFUs quantified 
on PAO1::SpyCas9 + vector expressing the JBD30 C repressor. Phage output is represented 
as the mean of 3 biological replicates ± SD. ND, not detectable. 
 (I) Schematic of the experimental design in G-H, where a high MOI of non-replicative “donor” 
phages is used to rescue a low MOI infection of wild-type “acceptor” phages.  
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Table 2.1. DMS3macr phage genotypes 
 
Phage acr gene source Acr Accession 
DMS3macrIE3 
(parent phage, no 
manipulation) 
DMS3m (gp30) WP_003723290.1 
 
DMS3macrIF1 JBD30 (gp35) YP_007392342.1 
 
DMS3macrIF2 MP29 (gp29) YP_002332454.1 
 
DMS3macrIF3  JBD88a (gp33) YP_007392440.1 
 
DMS3macrIF4 JBD26 (gp37) WP_016068584.1 
 
DMS3macrIF5 JBD5 (gp36) YP_007392740.1 
 
DMS3macrIF6 Pseudomonas  
aeruginosa strain PSE05 
(prophage) 
WP_043884810.1  
 
DMS3macrIF7 LPB1 (gp29) YP_009146150.1 
 
DMS3macrIIA4 Listeria monocytogenes 
J0161 (prophage)  
WP_003723290.1 
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Table 2.2. Plasmids used in this study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasmid Backbone  Purpose 
pAB02 pHERD30T crRNA overexpression: CRISPR2 
spacer 17 
pAB03 pHERD30T  crRNA overexpression: 
CRISPR2 spacer 20 
pAB58 pHERD30T generating DMS3macrIF2 
pAB59 pHERD30T generating DMS3macrIF3 
pAB21 pHERD20T generating DMS3macrIF4 
pJZ69 pHERD30T generating DMS3macrIF5 
pJZ70 pHERD30T generating DMS3macrIF6 
pAB24 pHERD20T generating DMS3macrIF7 
pJZ69 pHERD30T generating DMS3macrIIA4 
pAB45 pHERD20T generating DMS3macr gp52::gent 
pAB77,78 pHERD20T and 30T C repressor (JBD30) 
overexpression 
pAB79,80 pHERD20T and 30T C repressor (DMS3) 
overexpression 
pBAO72 pMMB67HE sgRNA targeting DMS3m  
pBAO95 pUC18T-mini-Tn7T-Gm Insertion of SpyCas9 into the 
PAO1 tn7 site  
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Chapter 3: Discovery of widespread Type I and Type V CRISPR-Cas inhibitors  
 
ABSTRACT 
Bacterial CRISPR-Cas systems protect their host from bacteriophages and other mobile genetic 
elements. Mobile elements, in turn, encode various anti-CRISPR (Acr) proteins to inhibit the 
immune function of CRISPR-Cas. To date, Acr proteins have been discovered for type I 
(subtypes I-D, I-E, and I-F) and type II (II-A and II-C) but not other CRISPR systems. Here we 
report the discovery of 12 acr genes, including inhibitors of type V-A and I-C CRISPR-Cas 
systems. The acr genes reported here provide useful biotechnological tools and mark the 
discovery of acr loci in many bacteria and phages.   
MAIN 
The discovery of bacterial CRISPR-Cas systems that prevent infection by bacterial 
viruses (phages) has opened a paradigm for bacterial immunity while yielding exciting tools for 
targeted genome editing. CRISPR systems destroy phage genomes, and in turn, phages 
express anti-CRISPR (Acr) proteins that directly inhibit Cas effectors1,2. Six distinct types (I-VI) 
of CRISPR systems are spread widely across the bacterial world 3, but Acr proteins have only 
been discovered for type I and II CRISPR systems 1,3-6. Given the prevalence and diversity of 
CRISPR systems, we predict that Acr proteins against other types await discovery. 
Anti-CRISPR proteins do not have conserved sequences or structures and only share 
their relatively small size, making de novo prediction of acr function challenging 6. However, acr 
genes often cluster together with other acr genes or are adjacent to highly conserved anti-
CRISPR associated genes (aca genes, Table 3.1) in “acr loci” 7,8. In this work, we sought to 
identify acr genes in bacteria and phages that are not homologous to previously identified acr or 
aca genes.  
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 Acr proteins were first discovered in Pseudomonas aeruginosa, inhibiting type I-F and I-
E CRISPR systems 1,9. P. aeruginosa strains also encode a third CRISPR subtype (type I-C), 
which lacks known inhibitors 10. We engineered P. aeruginosa to target phage JBD30 with type 
I-C CRISPR-Cas and used it in parallel with existing type I-E (strain SMC4386) and I-F (strain 
PA14) CRISPR strains to screen for additional acr candidates. 
 Homologs of aca1 were searched for in Pseudomonas genomes, and 7 gene families 
not previously tested for anti-CRISPR function were identified upstream of aca1 (Fig. 3.1A). 
Three genes inhibited the type I-E CRISPR-Cas system (acrIE5-7), one inhibited type I-F 
(acrIF11), restoring the plaquing of a targeted phage, and two genes had no inhibitory activity 
(orf1, orf2) (Fig. 3.1B, Table 3.2). Another gene exhibited dual I-E and I-F inhibition, and 
domain analysis revealed a chimera of previously identified acrIE4 and acrIF7 (acrIE4-F7). No 
type I-C inhibitors were identified. The type I-F inhibitor acrIF11 was commonly represented in 
both the P. aeruginosa mobilome and in over 50 species of diverse Proteobacteria (Fig. 3.2, 
Table 3.3). acrIF11 is often associated with genes encoding DNA-binding motifs, which we have 
designated aca4-7 (Table 3.1, Table 3.4). To confirm that these aca genes can be used to 
facilitate acr discovery, we used aca4 to discover an additional Pseudomonas anti-CRISPR, 
acrIF12 (Fig. 3.1A-B).  
Given the widespread nature of acrIF11, we next used it to discover Acr proteins against 
CRISPR systems where they have not yet been found: type I-C, a minimal Class 1 system and 
type V-A CRISPR-Cas12a (Cpf1), a Class 2 single effector system that has high efficiency in 
genome editing 11-13. To find AcrIC and AcrVA proteins, we first searched for genomes encoding 
CRISPR spacers that match a target protospacer elsewhere in the same genome (Fig. 3.3A). 
The tolerance of this “self-targeting” in viable bacteria indicates potential inhibition of the 
CRISPR system 4, since genome cleavage would result in bacterial death.  
The Gram negative bovine pathogen Moraxella bovoculi 14,15 is a Cas12a–containing 
organism 11 where four of the seven genomes feature Type V-A self-targeting, and one strain 
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(58069) also features self-targeting by type I-C. Although no previously described acr or aca 
genes were present in this strain, an acrIF11 homolog was found in phages infecting the human 
pathogen M. catarrhalis 16, a close relative of M. bovoculi. Genes adjacent to acrIF11 in M. 
catarrhalis had homologs in the self-targeting M. bovoculi strains (Fig. 3.3B), and together these 
genes were selected as candidate acr genes. Genes were screened against type I-C and I-F 
systems introduced above, as well a heterologous M. bovoculi Type V-A system that was 
transplanted into a strain of P. aeruginosa.  Using this panel of strains, we successfully 
identified Type I-C (AcrIC1), Type I-F (AcrIF13-14), and Type V-A inhibitors (AcrVA1-3) (Fig. 
3.3C-E). This discovery of Type V-A inhibitors in M. bovoculi was in good agreement with the 
independent discovery of AcrVA1 reported in a companion paper17  
AcrVA1 inhibits Cas12a in bacteria, and it also potently inhibits Cas12a in human cells18. 
This strong inhibitory activity may stem from the unique mechanism of action of AcrVA1. 
AcrVA1 is a multiturnover enzyme which cleaves the guide RNA, leaving Cas12a unable to find 
target DNA19,20. This makes AcrVA1 the first enzymatic anti-CRISPR to be described, though we 
hypothesize many mobile genetic elements may need to employ multi-turnover Acrs to protect 
themselves from CRISPR-Cas immunity. Previous work has shown that stoichiometric inhbitors 
require phage cooperation to fully neutralize CRISPR-Cas immunity21, a strategy that is highly 
dependent on local phage concentration and multiplicity of infection. This concentration 
dependent strategy is likely unsuitable for classes of mobile genetic elements have low 
reproductive rates, such as phages with small burst sizes. MGEs that cannot multiply infect 
cells, such as plasmids, would also be at a disadvantage. A prediction then is that plasmids and 
phages with small burst sizes may be especially likely to require hyper-potent mechanisms of 
immune neutralization. Future work should explore the autonomy that hyper-potent Acrs could 
provide to MGEs, and diverse MGEs should continue to be mined for new Acrs as they will likely 
yeild new and exciting mechanisms of CRISPR-Cas neutralization.  
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Here we report the discovery of a broadly distributed type I-F Acr protein (AcrIF11) that 
served as a marker for acr loci and led to the identification of type I-C and V-A CRISPR 
inhibitors. One of these acrVA genes (acrVA1) is a potent RNase19,20  that inhibits Cas12a in 
bacteria and human cells18. The strategy described herein enabled the identification of many 
widespread anti-CRISPR proteins, which may prove useful in future anti-CRISPR discovery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
85 
REFERENCES 
1. Bondy-Denomy, J., Pawluk, A., Maxwell, K. L. & Davidson, A. R. Bacteriophage genes 
that inactivate the CRISPR/Cas bacterial immune system. Nature 493, 429–432 (2013). 
2. Bondy-Denomy, J. et al. Multiple mechanisms for CRISPR-Cas inhibition by anti-CRISPR 
proteins. Nature 526, 136–139 (2015). 
3. Koonin, E. V., Makarova, K. S. & Zhang, F. Diversity, classification and evolution of 
CRISPR-Cas systems. Curr Opin Microbiol 37, 67–78 (2017). 
4. Rauch, B. J. et al. Inhibition of CRISPR-Cas9 with Bacteriophage Proteins. Cell 168, 
150–158.e10 (2017). 
5. Pawluk, A. et al. Naturally Occurring Off-Switches for CRISPR-Cas9. Cell 167, 1829–
1838.e9 (2016). 
6. Borges, A. L., Davidson, A. R. & Bondy-Denomy, J. The Discovery, Mechanisms, and 
Evolutionary Impact of Anti-CRISPRs. Annual Review of Virology 4, 37–59 (2017). 
7. Pawluk, A., Davidson, A. R. & Maxwell, K. L. Anti-CRISPR: discovery, mechanism and 
function. Nat Rev Micro 16, 12–17 (2018). 
8. Pawluk, A. et al. Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in diverse 
bacterial species. Nature Microbiology 1, 1–6 (2016). 
9. Pawluk, A., Bondy-Denomy, J., Cheung, V. H. W., Maxwell, K. L. & Davidson, A. R. A 
new group of phage anti-CRISPR genes inhibits the type I-E CRISPR-Cas system of 
Pseudomonas aeruginosa. mBio 5, e00896–e00896–14 (2014). 
10. van Belkum, A. et al. Phylogenetic Distribution of CRISPR-Cas Systems in Antibiotic-
Resistant Pseudomonas aeruginosa. mBio 6, e01796–15 (2015). 
11. Zetsche, B. et al. Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas 
System. Cell 163, 759–771 (2015). 
  
 
86 
12. Fonfara, I., Richter, H., Bratovič, M., Le Rhun, A. & Charpentier, E. The CRISPR-
associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. Nature 
532, 517–521 (2016). 
13. Kleinstiver, B. P. et al. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in 
human cells. Nature Biotechnology 34, 869–874 (2016). 
14. Angelos, J. A., Spinks, P. Q., Ball, L. M. & George, L. W. Moraxella bovoculi sp nov, 
isolated from calves with infectious bovine keratoconjunctivitis. Int. J. Syst. Evol. 
Microbiol. 57, 789–795 (2007). 
15. Dickey, A. M. et al. Large genomic differences between Moraxella bovoculi isolates 
acquired from the eyes of cattle with infectious bovine keratoconjunctivitis versus the 
deep nasopharynx of asymptomatic cattle. Vet. Res. 47, 31 (2016). 
16. Ariff, A. et al. Novel Moraxella catarrhalis prophages display hyperconserved non-
structural genes despite their genomic diversity. BMC Genomics 16, 860 (2015). 
17. Watters, K.E. et al. Systematic discovery of natural CRISPR-Cas12a inhibitors. Science 
362, 236–239 (2018). 
18. Marino, N.D. et al. Discovery of widespread type I and type V CRISPR-Cas inhibitors . 
Science 362, 240–242 (2018). 
19. Zhang, H. et al. Structural basis for the Inhibition of CRISPR-Cas12a by Anti-CRISPR 
Proteins. Cell Host & Microbe 25, 815–826 (2019). 
20. Knott, G.J. et al. Broad-spectrum enzymatic inhibition of CRISPR-Cas12a. Nat. Struct. 
Mol. Bio.  4, 315–321 (2019). 
21. Borges, A.L. et al. Bacteriophage cooperation suppresses CRISPR-Cas3 and Cas9 
immunity. Cell  174, 917–925 (2018) 
 
 
  
 
87 
Materials and Methods 
Bacterial strains and growth conditions 
Pseudomonas aeruginosa strains UCBPP-PA14 (PA14), SMC4386, and PAO1 were used in 
this study. The strains were grown at 37 °C in lysogeny broth (LB) agar or liquid medium, 
which was supplemented with 50 µg ml−1 gentamicin, 30 µg ml−1 tetracycline, or 250 
µg ml−1 carbenicillin as needed to retain plasmids or other selectable markers.   
 
Phage isolation 
Phage lysates were generated by mixing 10 µl phage lysate with 150 µl overnight culture of P. 
aeruginosa and pre-adsorbing for 15 min at 37 °C. The resulting mixture was then added to 
molten 0.7% top agar and plated on 1% LB agar overnight at 30 °C or 37 °C. The phage 
plaques were harvested in SM buffer, centrifuged to pellet bacteria, treated with chloroform, and 
stored at 4 °C. 
 
Bacterial transformations 
Transformations of P. aeruginosa strains were performed using standard electroporation 
protocols. Briefly, one mL of overnight culture was washed twice in 300 mM sucrose and 
concentrated tenfold. The resulting competent cells were transformed with 20 – 200 ng plasmid, 
incubated in antibiotic-free LB for 1 hr at 37 °C, plated on LB agar with selective media, and 
grown overnight at 37 °C. Bacterial transformations for cloning were performed using E. coli 
DH5α (NEB) and E. coli Stellar competent cells (Takara) according to the manufacturer’s 
instructions.  
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Discovery of acr genes using aca1 
All bacterial genome sequences used in this study were downloaded from NCBI. BLASTp was 
used to search the nonredundant protein database for Aca1 homologs (seed Aca1 accession: 
YP_007392343.1, e value < 0.005) in Pseudomonas sp. (taxid: 286) Individual genomes 
encoding an Aca1 homolog were then manually surveyed for aca1 associated genes. This 
approach was extended to discover the Aca4 (WP_034011523.1) associated anti-CRISPR 
AcrIF12. tBLASTn searches to identify orthologs of VA2 in self-targeting Moraxella bovoculi 
strains were performed using the protein sequence in Moraxella catarrhalis BC8 strain 
(EGE18855.1) as the query and Moraxella bovoculi genome accessions as the subject 
(accessions: 58069 genome, CP011374.1; 58069 plasmid, CP011375.1; 22581, CP011376.1; 
33362, CP011379.1; 28389, CP011378.1). Other searches for orthologs in Moraxella sp. were 
performed using BLASTp. 
 
Discovery of anti-CRISPR associated (aca) gene families  
Genomes with homologs of AcrIF11 were manually examined for novel anti-CRISPR associated 
(aca) genes. A gene was designated as an aca if it fit the following criteria: I) directly 
downstream of an AcrIF11 homolog in the same orientation, II) a non-identical homolog of this 
gene exists in the same orientation relative to a non-identical homolog of AcrIF11, and III) 
predicted in high confidence to contain a DNA-binding domain based on structural prediction 
using HHPred (probability >90%, E < 0.0005). Genes that fit these three criteria were then 
grouped into sequence families, requiring that a given gene have >40% sequence identity to at 
least one member of the family for family membership. 
 
Type I-C CRISPR-Cas expression in Pseudomonas aeruginosa 
Reconstitution of the Type I-C system from a P. aeruginosa isolate in the Bondy-Denomy lab 
into PAO1 was achieved by amplifying the four effector cas genes (cas3-5-8-7) from genomic 
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DNA by PCR and cloning the resulting fragment into the integrative, IPTG-inducible pUC18T-
mini-Tn7T-LAC plasmid to generate the pJW31 vector. This plasmid was then electroporated 
into PAO1 and chromosomal integration was selected for using 50 µg ml−1 gentamicin. After 
chromosomal integration of the insert was confirmed, the gentamicin selectable marker was 
removed using flippase-mediated excision at the flippase recognition target (FRT) sites of the 
construct; the resulting strain was named LL76. CRISPR RNAs (crRNAs) consisting of a spacer 
that targets JBD30 phage (see Table 3.5 for the sequence) and two flanking repeats were 
cloned into the mini-CTX2 (AF140577) vector, and the resulting vector was electroporated into 
LL76. Stable integration of the vector at the attB site was selected for using 30 
µg ml−1 tetracycline. Targeting was confirmed in the resulting strain (LL77) using phage 
challenge assays, as described in the “bacteriophage plaque assays” section.  
 
Type V-A CRISPR-Cas expression in Pseudomonas aeruginosa 
Human codon-optimized MbCas12a (Moraxella bovoculi 237) was amplified from the pTE4495 
plasmid (Addgene #80338) by PCR and cloned into pTN7C130, a mini-Tn7 vector that 
integrates into the attTn7 site of P. aeruginosa. The pTN7C130 vector expresses MbCas12a off 
the araBAD promoter upon arabinose induction and contains a gentamicin selectable marker. 
The resulting construct, pTN7C130-MbCas12a, was used to transform the PAO1 strain of P. 
aeruginosa, and stable integration of the vector was selected for using 50 µg ml−1 gentamicin 
and confirmed by PCR. After integration, flippase was used to excise the gentamicin selectable 
marker from the flippase recognition target (FRT) sites of the construct.    
 
CRISPR RNAs (crRNAs) for MbCas12a were generated by designing oligonucleotides with 
spacers that target gp23 and gp24 (see Table 3.5 for sequences) in JBD30 phage flanked by 
two direct repeats of the MbCas12a crRNA. The flanking repeats consist only of the sequence 
retained after crRNA maturation. The oligos were annealed and phosphorylated using T4 
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polynucleotide kinase (PNK) and ligated into NcoI and HindIII sites of pHERD30T. A fragment of 
the resulting plasmid that includes the araC gene, pBAD promoter, and crRNA sequence was 
then amplified by PCR and cloned into the mini-CTX2 plasmid. The resulting constructs were 
then used to transform the PAO1 tn7::MbCas12a strain, and stable integration was selected for 
using 30 µg ml−1 tetracycline. The parental strain encoding MbCas12a but no crRNA was used 
as the “no crRNA” control.   
 
Cloning of candidate anti-CRISPR genes 
All candidate genes were cloned into the pHERD30T shuttle vector, which replicates in both E. 
coli and P. aeruginosa. Novel genes found upstream of aca1 in Pseudomonas sp. were 
synthesized as gBlocks (IDT) and cloned into the SacI/PstI site of pHERD30T, which has an 
arabinose-inducible promoter and gentamicin selectable marker. Candidate genes derived from 
Moraxella bovoculi strains were amplified from the genomic DNA of 58069 and 22581 by PCR, 
whereas genes derived from Moraxella catarrhalis were synthesized as gBlocks (IDT). These 
inserts were cloned using Gibson assembly into the NcoI and HindIII sites of pHERD30T. All 
plasmids were sequenced using primers outside of the multiple cloning site. All constructs are 
listed in Table 3.5. 
 
Bacteriophage plaque assays 
Plaque assays were performed using 1.5% LB agar plates and 0.7% LB top agar, both of which 
were supplemented with 10 mM MgSO4. 150 ul overnight culture was resuspended in 3-4 ml 
molten top agar and plated on LB agar to create a bacterial lawn. Ten-fold serial dilutions of 
phage were then spotted onto the plate and incubated overnight at 30 °C. Agar plates and/or 
top agar were supplemented with 0.5 – 1mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and 
0.1-0.3% arabinose for assays performed with the LL77 (I-C) strain and with 0.1-0.3% arabinose 
for assays performed with the SMC4386 (I-E), PA14 (I-F), and PAO1 tn7::MbCas12a (V-A) 
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strains. The PA14 ΔCRISPR1ΔCRISPR2 (SMC5454) strain, which lacks its endogenous 
CRISPR arrays 1 and 2, was used as the “no crRNA” control for type I-F assays. PAO1 strains 
encoding MbCas12a but no crRNA were used as the “no crRNA” control for type V-A assays. 
For type I-C assays, the “uninduced” control was plated on agar lacking IPTG. Agar plates were 
supplemented with 50 µg ml−1 gentamicin for pHERD30T retention, as specified in the text. Anti-
CRISPR activity was assessed by measuring replication of the CRISPR-sensitive phages 
JBD30 (V-A, I-C), JBD8 (I-E) and DMS3m (I-F) on bacterial lawns relative to the vector control. 
JBD30, JBD8, and DMS3m are closely related phages, differing slightly at protospacer 
sequences. Plate images were obtained using Gel Doc EZ Gel Documentation System (BioRad) 
and Image Lab (BioRad) software. 
 
Phylogenetic reconstructions 
Homologs of AcrIF11 (accession: WP_038819808.1) were acquired through 3 iterations of 
psiBLASTp search the non-redundant protein database. Only hits with > 70% coverage and an 
E value < 0.0005 were included in the generation of the position specific scoring matrix (PSSM). 
A non-redundant set of high confidence homologs (> 70% coverage, E value < 0.0005) 
represented in unique species of bacteria were then aligned using NCBI COBALT using default 
settings  and a phylogeny was generated in Cobalt using the fastest minimum evolution method 
employing a maximum sequence difference of 0.85 and Grishin distance to calculate the tree. 
The resulting phylogeny was then displayed as a phylogenetic tree using iTOL: Interactive Tree 
of Life.  
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Figure 3.1. The discovery of a widespread Type I inhibitor  
(A) The associations of novel Type I-E (IE5-7) and Type I-F (IF11-12) anti-CRISPRs with anti-
CRISPR associated (Aca1, Aca4) genes in Pseudomonas sp. AcrIE4-7 is a chimera of two 
previously characterized Type I anti-CRISPRs (IE4 and IF7), and ORF1 and ORF2 did not 
manifest anti-CRISPR activity.  
(B) 10-fold serial dilutions of a Type I-E ,Type I-F, or Type I-C CRISPR-targeted phage (ϕ JBD8 
and ϕ DMS3m, ϕ JBD30 respectively) plated on lawns of Pseudomonas aeruginosa expressing 
the indicated CRISPR-Cas systems. A restoration of phage plaquing relative to the vector 
control indicates inhibition of CRISPR-Cas immunity by the expression of the specified plasmid-
borne anti-CRISPR. Phages were spotted on (-) CRISPR-Cas strains to measure phage 
replication in the complete absence of CRISPR-Cas immunity (bottom row). 
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Figure 3.2. AcrIF11 phylogenetic tree 
 An unrooted phylogenetic tree of full-length homologs of AcrIF11 with all branches labeled with 
species names. Species in which AcrIF11 is associated with a novel aca gene (aca4-7) are 
marked with asterisks.  
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Figure 3.3. Guilt-by-association in self-targeting strains leads to Type V-A and Type I-C 
anti-CRISPR proteins 
(A) Moraxella bovoculi exhibits intragenomic self-targeting, which is the co-occurrence of a 
spacer encoded by an apparently functional CRISPR-Cas12 system and its target protospacer 
within the same genome.  
(B) Schematic showing the presence of AcrIF11 orthologs in anti-CRISPR loci within Moraxella 
catarrhalis and the use of guilt-by-association to unveil novel Type V-A and Type I-C inhibitors 
in Moraxella bovoculi.  
(C) Tenfold serial dilutions of JBD30 phage were applied to bacterial lawns of P. aeruginosa 
PAO1 strain engineered to express MbCas12a, phage-targeting crRNA, and a candidate gene 
or vector control. “No crRNA” control was included to demonstrate loss of Cas12a targeting.  
(D) Tenfold serial dilutions of JBD30 phage were applied to bacterial lawns of P. aeruginosa 
PAO1 strain engineered to express the Type I-C system upon induction with IPTG as well as 
phage-targeting crRNA and a candidate gene or vector control. Uninduced control lacks IPTG. 
(E) Tenfold serial dilutions of DMS3m phage were applied to bacterial lawns of P. aeruginosa 
strain UCBPP-PA14 transformed with candidate gene or vector control. PA14ΔCRISPR-Cas 
strain was included as a control for loss of targeting.  
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Table 3.1. A table of previously discovered aca genes (aca1-3) and novel aca genes found 
in this study (aca4-7) 
All aca proteins are predicted with high confidence to contain helix-turn-helix motifs as predicted 
by HHPred.  
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Table 3.2. Protein sequences and accession numbers of Acr and Aca proteins found in 
this study 
 
Name Accession Protein Sequences 
AcrIE4-F7 
 
WP_064584002.1 
 
MSTQYTYQQIAEDFRLWSEYVDTAGEMSKDEFNS
LSTEDKVRLQVEAFGEEKSPKFSTKVTTKPDFDGF
QFYIEAGRDFDGDAYTEAYGVAVPTNIAARIQAQA
AELNAGEWLLVEHEA 
AcrIE5 
 
WP_074973300.1 
 
MSNDRNGIINQIIDYTGTDRDHAERIYEELRADDRI
YFDDSVGLDRQGLLIREDVDLMAVAAEIE 
AcrIE6 
 
WP_087937214.1 
 
MNNDTEVLEQQIKAFELLADELKDRLPTLEILSPMY
TAVMVTYDLIGKQLASRRAELIEILEEQYPGHAADL
SIKNLCP 
AcrIE7 WP_087937215.1 
 
MIGSEKQVNWAKSIIEKEVEAWEAIGVDVREVAAF
LRSISDARVIIDNRNLIHFQSSGISYSLESSPLNSPIF
LRRFSACSVGFEEIPTALQRIRSVYTAKLLEDE 
AcrIF11 WP_038819808.1 
 
MSMELFHGSYEEISEIRDSGVFGGLFGAHEKETAL
SHGETLHRIISPLPLTDYALNYEIESAWEVALDVAG
GDENVAEAIMAKACESDSNDGWELQRLRGVLAV
RLGYTSVEMEDEHGTTWLCLPGCTVEKI 
AcrIF11.1 WP_033936089.1 
 
MEIFHTSPVEITTINTQGRFGEFLCFAADEYVMTA
GDHVTYRIKVDESDIIMAGSIFYHERAADLSGLVE 
RVMQLTGCDEDTAEELISQRIDVFNLDDIDASDAA
ELSWEIQAITAKAAKTLGFRGVSMQDEQGTCYMID 
MLGHDAELVRVK 
 
AcrIF11.2 EGE18857.1 MTTLYHGSHENTAPVIKIGFAAFLPADNVFDGIFAN
GDKNVARSHGDFIYAYEVDSIATNDDLDCDEAIQII
AKELYIDEETAAPIAEAVAYEESLAEFEEHIMPRSC
GDCADFGWEMQRLRGVIARKLGFDAVECVDEHG
VSHLIVNANIRGSIA 
 
AcrIF12 ABR13388.1 
 
MAYEKTWHRDYAAESLKRAETSRWTQDANLEWT
QLALECAQVVHLARQVGEELGNEKIIGIADTVLSTI
EAHSQATYRRPCYKRITTAQTHLLAVTLLERFGSA
RRVANAVWQLTDDEIDQAKA 
AcrIF13 EGE18854.1  
 
MKLLNIKINEFAVTANTEAGDELYLQLPHTPDSQH
SINHEPLDDDDFVKEVQEICDEYFGKGDRTLARLS 
YAGGQAYDSYTEEDGVYTTNTGDQFVEHSYADY
YNVEVYCKADLV 
 
AcrIF14 
 
AKI27193.1  
 
MKKIEMIEISQNRQNLTAFLHISEIKAINAKLADGVD
VDKKSFDEICSIVLEQYQAKQISNKQASEIFETLAK
ANKSFKIEKFRCSHGYNEIYKYSPDHEAYLFYCKG
GQGQLNKLIAENGRFM 
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Name Accession 
 
Protein Sequences 
 
Orf1(Pse) 
 
 
SDJ61947.1 
 
 
MGVVVVLIIRLKARWSLHLERKLGEAGKAGIWEFH
RSESSYTTDGRTTFRNAALRPAEPKEGQTVEVFIC
SDSREPEEQWRAVGEGVARYE 
 
Orf2(Pse) WP_084336955.1 
 
MLSVLFFWLYFYALFFIRFASSNKRARGRGMQRP
ALVSIALEWGMRRELMSRSFTTRIDHLQEVSRLGR
GVARLRLGHSGRNLMPLILERRDGTGLTLKLDPKA
DPDEALRQLARGGIHVRVYSKYGERMRVVVDAP
QAISILRDELVDRE 
 
Aca1 YP_007392343 
 
MRFPGVKTPDASNHDPDPRYLRGLLKKAGISQRR
AAELLGLSDRVMRYYLSEDIKEGYRPAPYTVQFAL
ECLANDPPSA 
 
Aca2 WP_019933869.1 
 
MTHYELQALRKLLMLEVSEAAREIGDVSPRSWQY
WESGRSPVPDDVANQIRNLTDMRYQLLELRTEQI
EKAGKPIQLNFYRTLDDYEAVTGKRDVVSWRLTQ
AVAATLFAEGDVTLVEQGGLTLE 
 
Aca3 WP_049360086.1 
 
MKKFEAPEIGYTPANLKALRKQFGLTQAQVAEITG
TKTGYSVRRWEAAIDAKNRADMPLVKWQKLLDSL
K 
 
Aca4  ABR13385.1 
 
MTEEQFSALAELMRLRGGPGEDAARLVLVNGLKP
TDAARKTGITPQAVNKTLSSCRRGIELAKRVFT 
 
Aca5 WP_039494319.1 
 
MSLTEYIDKNFAGNKAAFARHMGVDAQAVNKWIK
SEWFVSTTDDNKIYLSSVRREIPPVA 
 
Aca6 WP_035450933.1 
 
MTAMKEWRARMGWSQRRAAQELGVTLPTYQSW
EKGIRLSDGSPIDPPLTALLAAAAREKGLPPIS 
 
Aca7 WP_064702654.1 
 
MIDARKHYDPNLAPELVRRALAVTGTQKELAERLD
VSRTYLQLLGKGQKSMSYAVQVMLEQVIQDGET 
 
AcrIC1 AKG19229.1  MNNLKKTAITHDGVFAYKNTETVIGSVGRNDIVMAI
DATHGEFNDKNFIIYADTNGNPIYLGYAYLDDNND
AHIDLAVGACNEDDDFDEKEIHEMIAEQMELAKRY
QELGDTVHGTTRLAFDDDGYMTVRLDQQAYPDY
RPENDDKHIMWRALALTATGKELEVFWLVEDYED
EEVNSWDFDIADDWREL 
 
Orf1(Mor) EGE18856.1 
 
MSKNKTPDYVLRANANYRKKHTTNKSLQLHNEKD
ADIIQALQNETKSFNALMKDILRNHYNLNQNQ 
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Name Accession Protein Sequences 
Orf2(Mor) AKG19231.1 MNNPKTPEYTRKAIRAYEKNLVRKSVTFDVRKDD
DMELLKMIEQDGRTFAQIARTALLEHLQK 
 
AcrVA1 AKG19227.1 MYEAKERYAKKKMQENTKIDTLTDEQHDALAQLC
AFRHKFHSNKDSLFLSESAFSGEFSFEMQSDENS
KLREVGLPTIEWSFYDNSHIPDDSFREWFNFANYS
ELSETIQEQGLELDLDDDETYELVYDELYTEAMGE
YEELNQDIEKYLRRIDEEHGTQYCPTGFARLR 
AcrVA2 AKG19228.1 MHHTIARMNAFNKAFANAKDCYKKMQAWHLLNK
PKHAFFPMQNTPALDNGLAALYELRGGKEDAHILS
ILSRLYLYGAWRNTLGIYQLDEEIIKDCKELPDDTP
TSIFLNLPDWCVYVDISSAQIATFDDGVAKHIKGFW
AIYDIVEMNGINHDVLDFVVDTDTDDNVYVPQPFIL
SSGQSVAEVLDYGASLFDDDTSNTLIKGLLPYLLW
LCVAEPDITYKGLPVSREELTRPKHSINKKTGAFVT
PSEPFIYQIGERLGSEVRRYQSIIDGEQKRNRPHT
KRPHIRRGHWHGYWQGTGQAKEFRVRW 
QPAVFVNSGRVSS 
AcrVA2.1 AKG12143.1 MHHTIARMNAFNKAFGNAKDCYKKMQAWHLNNK
PKHIFSPLQNTLSLNEGLAALYELHGGKEDEHILSI
LCCLYLYGTWRNTLGIYQLDEEIIKDCKELPDDTPT
SIFLNLPDWCVYVDISSAKIATIDGGVAKHIKGFWAI
YDNIEMHGVNHDVLNFIIDTDTDNNIYVPQSLILSS
EMSVAESLDYGLTLFGYDESNELVKGMLPYLLWL
CVAEPDITHKGLPVSREELTKPKHGINKKTGAFVT
PSEPFIYQIGERLGGEVRRYQSLIDDEKNQNRH 
HTKRPHIRRGHWHGYWQGTGQAKEFKVRWQPA
VFVNSGV 
AcrVA3 AKG19230.1 MVGKSKIDWQSIDWTKTNAQIAQECGRAYNTVCK
MRGKLGKSHQGAKSPRKDKGISRPQPHLNRLEY
QALATAKAKASPKAGRFETNTKAKTWTLKSPDNK
TYTFTNLMHFVRTNPHLFDPDDVVWRTKSNGVE
WCRASSGLALLAKRKKAPLSWKGWRLISLTKDNK 
 
AcrVA3.1 OOR90252.1  
 
MIAHQKNRRADWESVDWTKHNDEIAQLLSRHPDS
VAKMRTKFGAQGMAKRKPRRKYKVTRKAVPPPH
TQELATAAAKISPKSGRYETNVNAKRWLIISPSGQ
RFEFSNLQHFVRNHPELFAKADTVWKRQGGKRG
TGGEYCNASNGLAQAARLNIGWKGWQAKIIKG 
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Table 3.3 List of all accessions of AcrIF11 homologs, related to Figure 3.2 
List of the accession numbers for AcrF11 homologs represented in the AcrIF11 phylogenetic 
tree in Fig. 3.2. The species in which each listed accession is found is listed on the right. 
 
AcrIF11 Accession Species 
WP_038819808.1 Pseudomonas aeruginosa (AcrIF11) 
WP_102394900.1 Enterovibrio norvegicus 
WP_033936089.1 Pseudomonas aeruginosa (AcrIF11.1) 
WP_087698854.1 Chromobacterium violaceum 
WP_049175110.1 Acinetobacter ursingii 
WP_004681960.1 Acinetobacter parvus 
WP_062681378.1 Achromobacter xylosoxidans 
KTG25401.1 Idiomarina sp. 
WP_059284897.1 Aquitalea magnusonii 
WP_107732478.1 Chromobacterium haemolyticum 
WP_071971444.1 Alteromonas mediterranea 
WP_086652143.1 Acetobacter cibinongensis 
OHU91773.1 Pseudoalteromonas amylolytica 
WP_064700809.1 Halomonas sinaiensis 
WP_064702655.1 Halomonas caseinilytica 
WP_066478200.1 Comamonas terrae 
WP_068370878.1 Kerstersia gyiorum 
WP_057083778.1 Dickeya solani 
WP_074032235.1 Serratia fonticola 
WP_039494318.1 Pectobacterium carotovorum 
WP_077457760.1 Salinivibrio sp. IB872 
WP_064369479.1 Vibrio alginolyticus 
WP_041946990.1 Vibrio anguillarum 
WP_036292019.1 Methylosinus sp. PW1 
WP_017725053.1 Acinetobacter baumannii 
WP_061524032.1 Acinetobacter venetianus 
WP_004824702.1 Acinetobacter bereziniae 
WP_049556453.1 Yersinia kristensenii 
WP_109055423.1 Brenneria roseae 
WP_097468739.1 Escherichia coli 
OZT63688.1 Salmonella enterica 
PKT06451.1 Klebsiella pneumoniae 
WP_084913096.1 Rouxiella badensis 
WP_050090803.1 Yersinia pseudotuberculosis 
WP_050879812.1 Yersinia enterocolitica 
WP_050296286.1 Yersinia frederiksenii 
WP_079326564.1 Moraxella equi 
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AcrIF11 Accession Species 
WP_003671754.1 Moraxella catarrhalis (AcrIF11.2) 
WP_026949101.1 Alcanivorax sp. 
WP_092828131.1 Halomonas subterranea 
WP_027705017.1 Zymobacter palmae 
SMF80656.1 Pseudobacteriovorax antillogorgiicola 
WP_016360505.1 Bilophila wadsworthia 
SMC32303.1 Fulvimarina manganoxydans 
WP_051420249.1 Providencia alcalifaciens 
WP_060561196.1 Providencia stuartii 
WP_004247747.1 Proteus mirabilis 
WP_086368795.1 Photobacterium damselae 
WP_078005047.1 Izhakiella australiensis 
WP_018125160.1 Desulfovibrio oxyclinae 
OYL21963.1 Shigella sonnei 
PAY74230.1 Shigella flexneri 
CFQ72446.1 Yersinia similis 
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Table 3.4. List of Aca accessions 
Representative homologs of each Aca protein (Aca1-7) and its associated AcrIF11 homolog 
listed by accession number as well as the species of origin.  
 
Species Aca AcrIF11 accession Aca accession 
Pseudomonas aeruginosa Aca1  WP_038819808.1 WP_033971918.1 
Pseudomonas aeruginosa Aca4 WP_034011523.1 WP_079381596.1 
Pectobacterium carotovorum Aca5 WP_039494318.1  WP_039494319.1 
Yersinia frederiksenii Aca5  WP_050101208.1  WP_050101207.1 
Escherichia coli Aca5  WP_000765122.1 WP_012565004.1 
Serratia fonticola Aca5  WP_074032235.1 WP_074032234.1 
Dickeya solani Aca5  WP_057083778.1 WP_057083779.1 
Pectobacterium carotovorum Aca5  WP_039558031.1 WP_039558032.1 
Enterobacter cloacae complex Aca5  WP_045331704.1 WP_072050017.1 
Alcanivorax sp. Aca6 WP_026949101.1 WP_035450933.1 
Alcanivorax sp. Aca6  WP_063139756.1 WP_063139755.1 
Halomonas caseinilytica Aca7 WP_064702655.1 WP_064702654.1 
Halomonas sinaiensis Aca7  WP_064700809.1 WP_064700810.1 
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Table 3.5. Plasmids used for expression in Pseudomonas aeruginosa.   
 
Plasmid ID Plasmid use Backbone Description 
NM100 Express acrVA1  pHERD30T p30T-acrVA1 
NM101 Express acrVA2  pHERD30T p30T-acrVA2 
NM102 Express acrIC1  pHERD30T p30T-acrIC1 
NM103 Express acrVA3  pHERD30T p30T-acrVA3 
NM104 Express ORF2 (Mor)  pHERD30T p30T-ORF2 (Mor) 
NM105 Express acrIF13  pHERD30T p30T-acrIF13 
NM106 Express acrIF14  pHERD30T p30T-acrIF14 
NM107 Express VA2.1  pHERD30T p30T-acrVA2.1 
NM108 Express VA3  pHERD30T p30T-acrVA3 
NM109 Express VA3.1  pHERD30T p30T-acrVA3.1 
NM110 Type V-A crRNA -JBD30 gp23 mini-CTX2 mini-CTX2-crRNA g23 
NM111 Type V-A crRNA-JBD30 gp24 mini-CTX2 mini-CTX2-crRNA g24 
JDB500 Express MbCas12a (237) pTN7C130 pTN7-MbCas12a (VA) 
JDB501 
Type V-A crRNA - JBD30 
gp23 pHERD30T p30T-crRNA g23 
JDB502 Type V-A crRNA-JBD30 gp24 pHERD30T p30T-crRNA g24 
JZ_83 Express acrIE5  pHERD30T p30T-acrIE5 
JZ_99 Express acrIE6  pHERD30T p30T-acrIE6 
JZ_100 Express acrIE7  pHERD30T p30T-acrIE7 
JZ_127 Express ORF1 (Pse)  pHERD30T p30T- ORF1 (Pse) 
JZ_297 Express ORF2 (Pse)  pHERD30T p30T- ORF2 (Pse) 
JZ_298 Express acrIE4-IF7  pHERD30T p30T-acrIE4-IF7 
JZ_299 Express acrIF11  pHERD30T p30T-acrIF11 
JZ_300 Express acrIF12  pHERD30T p30T- acrIF12 
JZ_303 Express F11.1  pHERD30T p30T-acrIF11.1 
JZ_309 Express F11.2  pHERD30T p30T-acrIF11.2 
pJW31 
Express type I-C cas3-5-8-7 
genes  
pUC18T-mini-
Tn7T-LAC  pUC18T-cas3-5-8-7 
LL7724 
Express type I-C crRNA 
against JBD30 gp24 mini-CTX2 
mini-CTX2-crRNA g24 
(IC) 
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Chapter 4: Bacterial alginate regulators and phage homologs repress CRISPR-Cas 
immunity 
 
ABSTRACT 
CRISPR-Cas systems are adaptive immune systems that protect bacteria from bacteriophage 
(phage) infection1. To provide immunity, RNA-guided protein surveillance complexes recognize 
foreign nucleic acids, triggering their destruction by Cas nucleases2. While the essential 
requirements for immune activity are well understood, the physiological cues that regulate 
CRISPR-Cas expression are not. Here, a forward genetic screen identifies a two-component 
system (KinB/AlgB), previously characterized in regulating Pseudomonas aeruginosa alginate 
biosynthesis3,4, as a regulator of the expression and activity of the P. aeruginosa Type I-F 
CRISPR-Cas system. Downstream of KinB/AlgB, activators of alginate production AlgU (a σE 
orthologue) and AlgR, repress CRISPR-Cas activity during planktonic and surface-associated 
growth5. AmrZ, another alginate regulator6, is triggered to repress CRISPR-Cas immunity during 
surface-association. Pseudomonas phages and plasmids have taken advantage of this 
regulatory scheme, and carry hijacked homologs of AmrZ that repress CRISPR-Cas expression 
and activity. This suggests that while CRISPR-Cas regulation may be important to limit self-
toxicity, endogenous repressive pathways represent a vulnerability for parasite manipulation.  
 
MAIN 
Type I CRISPR-Cas systems are comprised of a multi-subunit RNA-guided surveillance 
complex, a trans-acting nuclease (Cas3)2,7,8, and proteins dedicated to spacer acquisition, Cas1 
and Cas29. Pseudomonas aeruginosa has become a powerful model organism for studying 
Type I CRISPR-Cas mechanisms10-15, functions16-19, evolution20-22, and interactions with phages 
utilizing anti-CRISPR proteins23-26. The P. aeruginosa strain PA14 possesses a naturally active 
Type I-F CRISPR-Cas immune system, comprised of two CRISPR arrays, an operon encoding 
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surveillance complex subunits Csy1-412, and a separate operon encoding Cas1 and a Cas2-3 
fusion protein. Quorum sensing has been shown to activate CRISPR-Cas expression in 
Pseudomonas aeruginosa27, as well as other species of bacteria28. However, little is known 
regarding the factors that temper CRISPR-Cas activity and mitigate the risk of acquiring and 
expressing a nucleolytic immune system. 
 
To discover new CRISPR-Cas regulators in P. aeruginosa, we utilized a P. aeruginosa strain 
PA14 engineered to express lacZ in place of the csy3 gene (csy3::lacZ) 17. This strain was 
subjected to C9 mariner transposon mutagenesis and ~40,000 colonies screened on X-gal 
plates. Multiple independent insertions were identified within lacZ and upstream genes (csy1 
and csy2), and thirty mutants with transposon insertions outside of this region were isolated and 
mapped (Table 4.1). Four independent insertions were identified in a single gene, kinB, which 
resulted in decreased β-galactosidase production on solid plates (Fig. 4.1a) and ~30% less 
csy3::lacZ activity in liquid culture compared to the unmutagenized parent (Fig. 4.1b). We 
selected kinB (a sensor kinase/phosphatase) for follow-up study as it was the only gene with >1 
independent transposon insertion and displayed the largest β-galactosidase activity change. 
 
We measured the ability of kinB::Tn insertions to limit the survival and replication of phage when 
introduced into the wild-type (CRISPR active) strain. Phages used to assay activity are: 
DMS3acrIE3 which is an untargeted control phage, DMS3macrIE318, which is fully targeted by the 
PA14 Type I-F CRISPR-Cas system, and phage DMS3macrIF4, which is partially targeted, by 
virtue of encoding a “weak” anti-CRISPR, acrIF4, that binds to the surveillance complex to 
inhibit CRISPR-Cas function23,25,29. The kinB::Tn strains remained resistant to DMS3macrIE3 
infection, but DMS3macrIF4 formed 10-fold more plaques relative to WT, demonstrating 
attenuated CRISPR-Cas activity (Fig. 4.1c, Fig. 4.2a). This defect was complemented by 
expression of kinB in trans (Extended Data Fig. 2c). Growth of control phage DMS3acrIE3 was not 
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impacted in the absence of kinB (Fig. 4.1c, Fig. 4.2a). Furthermore, two other phages that are 
partially targeted, JBD26 (naturally possessing acrIF4) and JBD25 (a phage with no Acr that is 
targeted by a weak spacer that provides incomplete immunity) also showed increased survival 
in the kinB:Tn strain (Fig. 4.1d) relative to WT PA14. Survival of a phage with a weak anti-
CRISPR or one that is targeted by a less active spacer is therefore a sensitive barometer for 
perturbations in CRISPR-Cas levels. Together, these data confirm that in the absence of kinB, 
csy gene expression and phage targeting are decreased. 
 
KinB is a sensor kinase/phosphatase in a two-component system with response regulator AlgB. 
The KinB/AlgB system has a large regulon within P. aeruginosa, and controls the biosynthesis 
of the extracellular polysaccharide alginate4. This pathway is well-studied due to the recurrent 
isolation of alginate-overproducing (mucoid) P. aeruginosa from the lungs of cystic fibrosis 
patients, where alginate plays an important role in the formation of antibiotic resistant biofilms 
during chronic infection. The absence of KinB function results in the accumulation of the 
phosphorylated form of the response regulator AlgB (P-AlgB), while the phosphorylation of AlgB 
has been attributed to unknown kinases30,31 (Fig. 4.2b).  P-AlgB activates the periplasmic 
protease AlgW (a DegS homolog), which degrades MucA, liberating sigma factor AlgU3,32,33 
(Fig. 4.2b). AlgU positively regulates many factors involved in alginate production, including 
AlgR, AlgD, AlgB, and AmrZ5,6,34.  
 
WT kinB or kinase inactive H385A kinB complemented an in-frame ∆kinB deletion, restoring 
CRISPR targeting of DMS3macrIF4 (Fig. 4.2c). However, a P390S kinB mutant incapable of 
dephosphorylating the response regulator AlgB did not complement, and in fact decreased 
CRISPR-Cas activity further (Fig. 4.2c). A ∆kinB∆algB double mutant restored CRISPR-Cas 
targeting to levels two-fold above WT (Fig. 4.3b), confirming the role of this signaling pathway. 
A strain lacking algB (∆algB) or possessing a D59N mutant that cannot be phosphorylated also 
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elevated CRISPR-Cas activity two-fold, supporting the repressive role of P-AlgB (Fig. 4.2d). 
These data show that accumulation of high levels of P-AlgB (achieved in kinB::Tn,  ∆kinB, or 
kinB P390S) leads to CRISPR-Cas repression. 
 
We next assayed anti-phage immunity in ∆algU and ∆algR backgrounds, revealing increased 
targeting of DMS3macrIF4 but not control phage DMS3acrIE3 in both knockouts (Fig. 4.2e). 
Complementation restored CRISPR-Cas levels (Fig. 4.2e), demonstrating that AlgU and AlgR 
repress CRISPR-Cas immunity. Double knockouts of each gene combined with ∆kinB also 
demonstrated increased CRISPR-Cas immunity, consistent with these factors acting as 
repressors downstream of KinB (Fig. 4.3a). All changes in DMS3macrIF4 phage replication and 
survival are CRISPR-dependent, as double knockouts (kinB, algB, algU, algR mutants 
combined with csy3::lacZ, a loss of function mutation) revealed plaquing equivalent to 
csy3::lacZ alone (Fig. 4.3b). β-galactosidase activity was measured in these strains during 
growth in liquid culture, revealing a peak in csy expression around 8 h, with repression of this 
operon during entry into stationary phase (Fig. 4.2f). As suggested by the phage targeting 
experiments, a marked increase in expression of the csy operon was noted for both ∆algR and 
∆algU strains, with a decrease in csy expression for ∆kinB.  
 
Next, we performed RT-qPCR of the cas3 and the csy3 transcripts in the mutant strains. We 
measured the relative abundance of Cas3 and Csy complex protein by fusing a sfCherry tag to 
the endogenous cas3 or csy1 gene in the mutant backgrounds, and used fluorescence as a 
proxy for protein abundance. We found that kinB loss decreased expression of both the cas3 
and csy operon, resulting in lower cas3 and csy3 transcripts and Cas3-sfCherry and Csy1-
sfCherry levels relative to WT (Fig. 4.4a,b). Conversely, we observed increased levels of cas3 
and csy3 transcripts and Cas3-sfCherry and Csy1-sfcherry in the ∆algR and ∆algU mutants 
relative to WT (Fig. 4.4a,b). These data demonstrate that this pathway controls the levels of 
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both Cas3 and the Csy complex in the bacterial cell by transcriptionally controlling the cas3 and 
csy operons.   
 
As Cas3-sfCherry was expressed at low levels relative to Csy1-sfCherry, and is also known to 
be subject to post-translational control by Cas114, we sought to dissect the relative contribution 
of nuclease versus surveillance complex disregulation in driving the immune phenotypes of the 
KinB/AlgB pathway mutants.  To specifically measure the anti-phage activity of the Csy 
complex, we developed a Cas3-indepedent bioassay to read out the activity of the surveillance 
complex in the cell. Through the rational design of crRNAs to target an early phage promoter 
(PE1, PE2), we observed inhibition of phage survival in a P. aeruginosa strain with a nuclease 
dead Cas3 (dCas3), while an ORF-targeting crRNA (ORF1) was ineffective (Fig. 4.4c). This 
CRISPR-based transcriptional interference (CRISPRi) effect was remarkably strong enough to 
completely limit phage replication in the absence of Cas3 nuclease activity for crRNA PE2. 
Phage inhibition via CRISPRi occurred when infecting with a phage that expressed the inhibitor 
of Cas3 recruitment, AcrIF3, but not an inhibitor that blocks Csy complex-phage DNA binding25, 
AcrIF1 (Fig. 4.4c). We selected PE1 as a moderately-functional CRISPRi spacer and expressed 
it in KinB/AlgB pathway mutants. We observed decreased CRISPRi activity against phage 
DMS3macrIF3 in the ∆kinB background, but increased CRISPRi in ∆algR and ∆algU, (Fig. 4.4d, 
compare F3 and F1 phage). This demonstrates modulation of csy gene expression is sufficient 
to impact phage targeting in a Cas3-independent manner. We conclude that the KinB/AlgB 
pathway regulates Cas3 and Csy complex levels, and repression of Csy complex levels has a 
large impact on anti-phage immunity.  
 
To identify downstream CRISPR-Cas regulators in the AlgU regulon35, we focused on another 
factor involved in alginate production,  the alginate and motility and regulator Z, amrZ6,36. We 
generated a knockout of amrZ and observed a CRISPR-dependent increase in efficiency of 
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immunity (EOI) against phage DMS3macrIF4 (Fig. 4.5a, Fig. 4.3b). This was complemented when 
amrZ was expressed in trans (Fig. 4.5a). A ∆kinB∆amrZ double knockout also showed 
increased CRISPR-Cas activity, consistent with its role as a repressor downstream of KinB (Fig. 
4.3a). However, when we measured cas3 and csy3 transcript levels and Cas3-sfCherry and 
Csy1-sfCherry levels in ∆amrZ, neither transcript or protein levels differed from WT (Fig. 
4.6a,b). In considering these discrepant results, we realized that the anti-phage plaque assay is 
performed on solid plates whereas RNA quantification and sfCherry fluorescence 
measurements were conducted on liquid culture samples. To measure anti-phage activity of 
∆amrZ in planktonic growth, we challenged WT and ∆amrZ with 106 PFU (MOI = 0.2) of virulent 
DMS3macrIF4 in liquid culture. Both strains succumbed to phage infection with similar kinetics 
(Fig. 4.5b), and phage replication did not differ significantly between the two strains (Fig. 4.5c). 
Phage replication in the absence of CRISPR-Cas immunity also did not differ between the two 
strains (Fig. 4.5c). This demonstrates that under our conditions, AmrZ does not control 
CRISPR-Cas during planktonic growth. 
 
To test the hypothesis that AmrZ is a surface-activated repressor of CRISPR-Cas, we measured 
the levels of Csy complex during surface association and planktonic growth in WT and ∆amrZ 
cells using an endogenous Csy1-sfCherry reporter over a period of 30 h. In WT cells, the levels 
of Csy complex were attenuated during surface-association relative to planktonic growth (~50% 
reduction of peak Csy1-cherry levels, Fig. 4.5d), but in the absence of AmrZ, Csy complex 
levels during surface association increased to levels comparable to those in planktonic growth 
(Fig. 4.5d). Deletion of amrZ did not impact Csy complex levels in liquid culture at any timepoint 
(Fig. 4.5e). To increase the levels of AmrZ during planktonic growth, we ectopically expressed 
AmrZ from a high copy plasmid, and measured the impact on the our transcriptional reporter 
csy3::lacZ and our translational reporters Csy1-sfCherry and Cas3-sfCherry. Here, high levels 
of AmrZ in liquid growth reduced β-galactosidase activity of the csy3::lacZ reporter (Fig. 4.6c) 
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and strongly limited expression of Csy1-sfCherry and Cas3-sfCherry (Fig. 4.5f). These results 
suggest that low AmrZ activity in planktonic growth underlies its surface-activated control of 
CRISPR-Cas. In contrast to AmrZ, overexpression of AlgU only moderately impacted Csy 
complex and Cas3 levels and AlgR did not impact the levels of either reporter when 
overexpressed (Fig. 4.5f).  
 
We next considered if phages and other mobile genetic elements had evolved mechanisms to 
manipulate this CRISPR-Cas repressive pathway. Inspired by the discovery of a 
Paraburkholderia phage that carried a distant homolog of AmrZ37, we searched the NCBI 
database for AmrZ homologs on Pseudomonas mobile genetic elements (MGE). Excitingly, we 
identified 14 diverse Pseudomonas mobile elements carrying AmrZ homologs (Table 4.2). 
These MGEs included obligately lytic and temperate Myophages, temperate Siphophages, and 
plasmids. AmrZ has been structurally characterized in complex with operator DNA38, and these 
mobile AmrZ homologs showed perfect conservation of critical DNA-interacting residues in the 
ribbon-helix-helix domain, suggesting conserved binding specificity (Fig. 4.7a, b, red 
residues/arrowheads). To test if these mobilized AmrZ variants were capable of regulating 
CRISPR-Cas activity in Pseudomonas aeruginosa, we assayed the ability of 6 MGE-encoded 
AmrZ homologs to complement the ∆amrZ strain. Five out of six homologs complemented the 
∆amrZ mutant to various degrees, indicating they were active in the PA14 transcriptional 
network and were bona fide CRISPR-Cas regulators (Fig. 4.7c). Next, each gene was 
expressed in WT cells, revealing 3 P. aeruginosa phage AmrZ homologs (AmrZPaBG, AmrZphi3, 
AmrZJBD68) inhibited Csy complex biogenesis (Fig. 4.7d).  
 
We next studied the anti-CRISPR function of these mobilized AmrZ homologs in the context of 
the phage life cycle. By inserting the two most potent phage AmrZ homologs, amrZphi3 and 
amrZPaBG into the anti-CRISPR locus of phage DMS3m, we compared the anti-CRISPR capacity 
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of these repressors relative to bona-fide Type I-F inhibitor AcrIF4 and the negative control 
inhibitor AcrIE3. While the AmrZ homologs provided no protection during lytic growth (likely 
because they cannot act on previously synthesized CRISPR-Cas complexes) (Fig. 4.7e), they 
were able to significantly reduce the expression and activity of the CRISPR-Cas complex during 
lysogeny (Fig. 4.7f,g). By lysogenizing a strain of PA14 with a catalytically dead Cas3 and an 
endogenously tagged copy of Csy1-sfCherry, we demonstrated that the presence of AmrZPhi3 or 
AmrZPaBG reduced Csy complex levels more than 50% of an unlysogenized control, while AcrIF3 
and AcrIF4 did not reduce Csy complex levels (Fig. 4.7f). To measure the activity of the Csy 
complex in these lysogens, we programmed the Csy complex to transcriptionally repress the 
phzM gene, which is responsible for the generation of the green pigment pyocyanin. De-
repression of phzM expression can be quantified by measuring accumulation of the pyocyanin 
pigment in an overnight culture. We found that AmrZPhi3 or AmrZPaBG de-repressed phzM to a 
similar extent as AcrIF4 (Fig. 4.7g), demonstrating anti-CRISPR activity for these hijacked 
CRISPR-Cas repressors.  
 
Regulation of bacterial processes is highly variable across species, reflecting niche-specific 
adaptations. Here, a genetic screen reveals that the KinB/AlgB two-component system 
regulates CRISPR-Cas in P. aeruginosa. Removal of KinB or inactivation of its phosphatase 
activity leads to the accumulation of P-AlgB, activating CRISPR-Cas repressors AlgU, AlgR, and 
AmrZ. This pathway also drives alginate production, which is responsible for the formation of the 
characteristic mucoid biofilms of cystic fibrosis P. aeruginosa isolates3,39,40. We show that P-
AlgB (via kinB deletion), AlgU, and AlgR repress CRISPR-Cas activity during surface-
association and planktonic growth, and AmrZ is triggered to further repress CRISPR-Cas during 
surface-association. Some Pseudomonas genetic parasites encode hijacked AmrZ homologs, 
which retain their ability to repress CRISPR-Cas expression and inhibit CRISPR-Cas biogenesis 
during lysogeny. Strikingly, we have identified multiply-lysogenized strains of Pseudomonas 
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aeruginosa with as many as 4 independent copies of AmrZ on mobile elements in addition to 
host AmrZ (Table 4.3). The evolutionary success of AmrZ in the Pseudomonas mobilome and 
core genome suggests a “guns for hire41” role for this gene in the arms race between bacteria 
and their parasites. 
We and others observe CRISPR-Cas activation27,28 during exponential growth, where phage 
infection risk is high (i.e. metabolically active, well-mixed planktonic culture21). Surface-
association lessens infection risk, as spatial structure limits phage dispersal and prevents a 
phage bloom from overtaking the entire bacterial population42. Though not measured here, 
spatial stratification and polysaccharide secretion in a mucoid biofilm likely also provide high 
levels of intrinsic phage resistance. 
The observation that CRISPR-Cas expression and surface-association/biofilm formation are 
inversely regulated is supported by our analysis of a previously published PA14 RNAseq data 
set43 and proteomic data set44, which show activation of CRISPR-Cas expression in exponential 
phase, and repression during stationary phase and biofilm growth at 24 and 48 h (Fig. 4.8a). 
Cas proteins are still detected in stationary phase and biofilm growth, suggesting the cells retain 
some immunity after transcriptional shutdown (Fig. 4.8b). Furthermore, previous studies show 
that the P. aeruginosa genome is hyper-sensitive to CRISPR-induced DNA damage during 
surface-association and biofilm formation, leading to cell death when a mismatched prophage 
sequence target is present in the chromosome16,17. This suggests that CRISPR auto-immunity 
costs are also dependent on the growth state and physical environment of the cell.  
Here, we identify a CRISPR-Cas repressive pathway in P. aeruginosa. We speculate that the 
ability to control CRISPR-Cas activity during lifestyle transitions may be essential for P. 
aeruginosa to safely maintain a CRISPR-Cas system by limiting self-toxicity.  In our discovery of 
MGE-encoded CRISPR-Cas repressors we reveal an unexpected cost to CRISPR-Cas 
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regulation: the evolution of CRISPR-Cas repression has created an Achilles Heel that is 
exploited by genetic parasites. 
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MATERIALS AND METHODS  
Bacterial strains and bacteriophages. P. aeruginosa UCBPP-PA14 (PA14) strains and E. Coli 
strains (Table 4.4) were grown on lysogeny broth (LB) agar or liquid at 37 oC. Media was 
supplemented with gentamicin (50 µg ml-1 for P. aeruginosa and 30 µg ml-1 for E. Coli) to 
maintain the pHERD30T plasmid or carbenicillin (250 µg ml-1) for P. aeruginosa or ampicillin 
(100 µg ml-1) for E. coli containing the pHERD20T plasmids. pHERD plasmids were induced 
with 0.1% arabinose. Bacteriophage stocks (Table 4.4) were prepared as described 
previously18. In brief, 3 ml of SM buffer was added to plate lysates of the desired purified 
bacteriophage and incubated at room temperature for 15 minutes. SM buffer containing phages 
was collected and 100 µl of chloroform was added. This was centrifuged at 10,000 x g for 5 
minutes and supernatant containing phages was transferred to a screw cap storage tube and 
incubated at 4 oC. 
 
Transposon mutagenesis screen. The csy::lacZ reporter strain was subjected to transposon 
mutagenesis and colonies were isolated on plates containing X-gal (5-bromo-4-chloro-3-indolyl-
β-D-galactopyranoside). ~50,000 colonies were visually examined for increased or decreased 
levels of β-galactosidase and insertions mapped by semi-random PCR. To conduct transposon 
mutagenesis, overnights of PA14 csy3::lacZ and E. coli containing the pBTK30 Tn suicide 
vector were mixed in a 1:2 ratio (donor : recipient) for conjugation. Mixed cells were centrifuged 
at 4,000 x g for 10 minutes to pellet cells. 100 µl of resuspended conjugation pellet was then 
spotted on LB agar plates and incubated at 37 oC for 6h. Conjugation spots were collected and 
resuspended in LB liquid media. Conjugation was then plated on an LB agar plates 
supplemented with nalidixic acid (30 µg ml-1) and gentamicin (50 µg ml-1). Surviving colonies 
containing Tn insertions were collected into 1ml of LB liquid media. Serial dilution of were 
prepared and plated on LB agar plates supplemented with x-gal (200 µg ml-1) and gentamicin 
(50 µg ml-1) and nalidixic acid (30 µg ml-1). Plates were incubated at 37 oC for 24 h to allow for 
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colonies to change color. Colonies displaying changed expression levels as compared to the 
unmutagenized parental strain (PA14 csy3::lacZ no pBTK30) were then isolated onto secondary 
LB agar plates with X-gal, gentamicin, and nalidixic acid at the stated concentrations. Genomic 
DNA (gDNA) was collected from isolated single colonies by resuspending bacterial colonies in 
0.02% SDS and boiling the sample for 15 minutes. Samples were then centrifuged at 10,000 x g 
and supernatants containing gDNA were collected. Transposon insertion junctions were 
mapped using semi-random PCR (Supplementary 2). PCR samples were sequenced and reads 
were then mapped to the P. aeruginosa UCBPP-PA14 genome using BLAST. Expression 
changes were then verified via modified β-galactosidase assay in liquid culture. 
 
Plaque assays. Plaque assays were performed on LB agar plates (1.5% agar) with LB top agar 
(0.7% agar), supplemented MgSO4 (10 mM final concentration) and gentamicin (50 µg ml-1)  and 
arabinose (0.1%) as needed for plasmid maintenance and induction. Spot titrations were done 
by mixing 150 µl of a P. aeruginosa overnight culture with 3 ml of top agar, which was dispersed 
evenly on a LB MgSO4 plate. 3 µl of 10-fold phage dilutions were then spotted on the surface. 
Plates were incubated overnight at 30 oC. To count plaques, full plate assays were used, except 
when CRISPR-targeting was so strong that discrete plaques could not be accurately measured. 
In this case, spot titrations are shown. For full plate assays, 10 µl of the phage dilution giving 
single plaques was incubated with 150 µl of P. aeruginosa overnight for 10 minutes at 37 oC. 3 
ml of top agar was then added and the mixture was dispersed evenly on a LB MgSO4 plate. 
Individual plaques were then counted to assess differences in efficiency of bacterial immunity 
and phage. Efficiency of immunity (EOI) of a bacterial mutant relative to WT was calculated by 
dividing the number of plaque-forming units (PFUs) formed on WT by the number of PFUs 
formed on the mutant strain. EOI>1 means less plaques formed on the mutant than on WT, so 
the mutant was more immune to phage infection than WT. EOI<1 means more plaques formed 
on the mutant, so the mutant was less immune to phage infection than WT. Efficiency of 
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plaquing (EOP) of a phage (Fig. 4.7e) was calculated by dividing the number of PFUs formed 
on WT (CRISPR+) by the number of PFUs formed on ∆CRISPR. An EOP of 1 means that 
CRISPR does not impact phage replication, and EOP of 0 means that the phage cannot 
replicate in the presence of CRISPR.  
 
β-galactosidase assay. A β-galactosidase assay described previously45 was used to measure 
lacZ activity in transcriptional fusions. Bacterial cultures were grown overnight at 37 oC. Cultures 
were then diluted 1:100 into LB liquid medium supplemented with the desired antibiotic, and 
incubated at 37 oC with shaking until the desired time point was reached. Culture density was 
measured with a spectrophotometer (OD600) and 200 µl of the sample was added to 800 µl of 
permeabilization solution. Cells were mixed via inversion and vortexed for 1 minute to 
permeabilize the cells. 200 µl of ONPG (4 mg ml-1) was added and samples were incubated at 
30 oC until sample turned yellow. Enzymatic reaction was stopped by addition of 300 µl of 1M 
Na2CO3. Samples were centrifuged at 13,000 x g for 5 minutes to remove debris and 200 µl of 
supernatant was moved to a 96-well plate to read absorbance at 420 nm and at 550 nm. Miller 
units were calculated using the Miller equation: (1000*OD420 nm -1.75*OD550 nm)/(Tmin* VmLs 
*OD600nm). 
 
Phage transduction of kinB::Tn alleles. Transposon insertions in kinB from a csy3::lacZ 
background were transduced into WT PA14 to enable testing of CRISPR-Cas function with the 
same transposon insertion. Phage phiPA3 was used to infect the donor strain (kinB::Tn), on 
plates with top agar overlays, using ~104 PFU to generate near confluent lysis. Plates were 
soaked in 3-4 mL of phage SM buffer and 2 mL collected over chloroform, vortexed, and 
pelleted to isolate transducing phage in the supernatant. Lysates were used to infect recipient 
strains (WT PA14). ~108 PFU were used to infect a culture at an MOI of 1. After 30 minutes of 
static incubation on the bench, cultures were gently shaken at 37 oC for 20 min and then 
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pelleted at 5000 x g. Cells were washed twice with LB, and subsequently incubated at 37 oC for 
1 hour to allow recombination and gentamicin resistance outgrowth. Cultures were pelleted and 
resuspended in 200 µL of LB, and plated on LB plates containing gentamicin. Controls included 
uninfected cells and cells infected with phages not propagated on a gentamicin resistant donor 
strain. Additionally, phage lysate was directly plated under selection to confirm no residual 
donor strain in the phage preparation. Plates were incubated overnight at 37 oC and their 
identity (i.e. CRISPR-Cas intact) confirmed with a plaque assay using DMS3macrIE3 as the target 
phage and PCR of the kinB locus.  
 
Introduction of csy3::lacZ P. aeruginosa UCBPP-PA14 strains. The lacZ gene was 
introduced into PA14 strains of interest via allelic replacement. Recombination vector pMQ30 
containing lacZ flanked by homology arms matching csy2 and csy4 was introduced via 
conjugation. PA14 strains and E. coli containing vector were mixed at a ratio of 1:2 
(recipient:donor). Mixture was heat shocked at 42 oC for 10 min. Mating spot was then plated on 
a LB agar plate and incubated overnight for 30 oC. Mating spot was then collected, resuspended 
in 1 ml of LB liquid media and plated on VBMM plates supplemented with 50 ug/mL gentamicin 
to select for colonies with the integrated homology plasmid. Colonies were cultured overnight in 
LB in the absence of selection at 37 oC, and were then diluted and counterselected on no salt 
LB (NSLB) agar plates supplemented with 15% sucrose. Surviving colonies were then grown on 
LB agar plates supplemented with gentamicin and X-gal to check for lacZ insertion via color 
change and lacZ insertion was further verified via PCR. 
 
Reverse transcriptase quantitative PCR (RT-PCR). Total RNA extracts were harvested using 
an acid-phenol chloroform extraction from liquid cultures subcultured 1:100 and grown for 8 h in 
LB media. RNA treated with DNAse (Ambion) to remove DNA and 1ng of total RNA was used in 
a series of RT-qPCR reactions. Reactions were conducted in a BioRad CFX connect qPCR 
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cycler, using clear BioRad plates with the Luna Universal One-Step Reaction Mix (NEB). A 
standard curve for each primer set was generated using pooled RNA samples. The 
housekeeping gene, rpsL, was used for normalization, and gene specific primers against cas3 
and csy3 (Table 4.5) were used to quantify expression from the cas and csy operons. For RT-
qPCR reactions, 1 ng of total RNA was used in each reaction, performed in triplicate. Reverse 
transcription was conducted using to generate cDNA using Luna WarmStart® RT Enzyme Mix 
(NEB).  Standard curves were used to calculate the relative abundance of target transcripts, and 
cas3 and csy3 transcript levels were then normalized to rpsL levels. 
 
Generation of endogenous Csy1-sfCherry and Cas3-sfCherry reporters 
Endogenous Csy1-sfCherry and Cas3-sfCherry reporters were constructed similar to the 
construction of csy3::lacZ. We initially verified that tagging of sfCherry at the N-terminus of Csy1 
and Cas3 are functional, when expressed from a plasmid. pMQ30-sfCherry-Csy1, which 
contains sfCherry sequence flanked by 657 bp upstream of csy1 and 701 bp downstream of 
csy1 start codon, was cloned in pMQ30 plasmid between HindIII and BamHI sites using Gibson 
assembly. pMQ30-sfCherry-Cas3, which contains sfCherry sequence flanked by 353 bp 
upstream of cas3 and 350 bp downstream of the cas3 start codon, was cloned in pMQ30 
plasmid between HindIII and BamHI sites using Gibson assembly. The 4 bp that overlap 
between the end of cas1 and the beginning of cas3 were duplicated in the final construct. Both 
pMQ30-sfCherry-Csy1 and pMQ30-sfCherry-Cas3 contains ggaggcggtggagcc sequence 
(encoding GGGGA) as linker between sfCherry and the respective tagged proteins. The Csy1-
sfCherry and Cas3-sfCherry construct were introduced into PA14 strains of interest via allelic 
replacement. Strains containing appropriate insertion were verified via PCR.  
 
sfCherry reporter profiling. Liquid: Cells were diluted 1:100 from an overnight culture into 
fresh LB (with 0.1% arabinose and 50 ug/mL gentimicin if required for plasmid induction and 
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maintenance), and grown for the indicated number of hours in biological triplicate. 500 µl of 
each sample was then spun down at 8,000xg for 2 minutes, and resuspended in 500 µl of M9 
media. Samples were loaded in to a 96 well plate  (150 µl /well) in technical triplicate and red 
fluorescence and OD600 were measured using a Biotek H4 Synergy 96 well plate reader. M9 
media alone was measured to obtain a background fluorescence and absorbance reading. 
Solid: Cells were diluted 1:100 from an overnight culture into fresh LB and 20 µl plated onto 
individual wells in biological triplicate in a 24 well plate with each well containing solidified 1.5% 
LB Agar (with 0.1% arabinose and 50 ug/mL gentimicin if required for plasmid induction and 
maintenance).  The 24 well plate was then covered with a breathable Aeraseal, and incubated 
at 37 oC with no shaking. At the indicated timepoint, cells were harvested by flooding each well 
with 500 µl of M9 buffer, and were spun down at 8,000xg for 2 minutes, and resuspended in 500 
µl of M9 media. Samples were loaded in to a 96 well plate  (150 µl /well) in technical triplicate 
and red fluorescence (excitation 580 nm, emission 610 nm) and OD600 were measured using a 
Biotek H4 Synergy 96 well plate reader. M9 media alone was measured to obtain a background 
fluorescence and absorbance reading. To calculate the relative fluorescence units for each 
sample, the background fluorescence and background OD600 values obtained were subtracted 
from the sample values, and the sample fluorescence was then normalized to the sample 
OD600.  
 
Generation of PA14 ΔamrZ using the endogenous I-F CRISPR-Cas system.  
Complementary oligonucleotides encoding a crRNA targeting the amrZ gene of PA14 were 
annealed and ligated into the multiple cloning site of the pHERD30T vector. A fragment 
possessing homology arms flanking the desired mutation (500 bp upstream and 500 bp 
downstream) around amrZ was cloned into a distinct location (NheI site) of the same vector via 
Gibson assembly. The new plasmid containing both a crRNA and homology region was 
introduced into WT PA14 via electroporation. Transformation efficiency dropped dramatically in 
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the presence of the crRNA due to the toxicity caused by self-targeting. All surviving colonies had 
the desired clean deletion of the amrZ gene. Deletions were confirmed by PCR of the region of 
interest and subsequent Sanger sequencing of the amplicon. A 2000 bp region flanking amrZ 
was PCR amplified and sequencing primers were designed to sequence both the deletion 
junction and outside of the original 500 bp flanking regions to confirm the removal of the amrZ 
gene. 
 
Liquid phage infection assay. Liquid phage infections were performed as described in29. In 
brief, an overnight culture of cells was diluted 1:100 into fresh media, and infected with 106 PFU 
virulent phage DMS3macrIF4 in biological triplicate in a 96 well Costar plate. Cells were incubated 
at 37 oC with constant rotation and OD600 measured every 5 minutes in a Biotek H4 Synergy 
plate reader. Phage were harvested from each well and quantified by plaque assay after 24 h. 
In these experiments, all strains used in the assay carried 2 spacers against the DMS3macrIF4 
phage to prevent phage escape: one endogenous spacer (CRISPR2_sp1), and the other spacer 
was provided on a pHERD30T plasmid. 
 
AmrZ homolog discovery and characterization. BLASTp was used to search the 
nonredundant protein database for AmrZ homologs (accession: ABJ12639.1) in Pseudmonas 
sp. (taxid: 286) in May 2019. This homolog list (e value > 0.001) was then examined for 
homologs found on phage or plasmid genomes. Representative homologs were aligned using 
Clustal and the alignment visualized in Jalview, and key conserved residues were mapped onto 
the structure in Pymol (PDB ID: 3QOQ). Select homologs were synthesized (TWIST 
Biosciences) and cloned into the SacI/PstI site of the arabinose-inducible plasmid pHERD30T 
using Gibson assembly. Vectors were electroporated into Pseudomonas aeruginosa strains for 
functional testing, where they were induced with 0.1% arabinose and maintained with 50 ug/mL 
gentimicin.  
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Construction of recombinant DMS3m AmrZ phages. Phages were generated as previously 
described29. Briefly, Gibson assembly was used to generate a recombination plasmid on 
pHERD 30T with amrZphi3 or amrZPaBG flanked by homology arms up and downstream of the 
DMS3m Acr locus. This plasmid was transformed into PA14 ∆CRISPR, and infected with phage 
DMS3macr-gent – a phage that is sick as the result of the insertion of a large gentimicin resistance 
cassette into its anti-CRISPR locus. Healthy plaques resulting from the recombination were 
screened for their incorporation of amrZphi3 or amrZPaBG into the anti-CRISPR locus with PCR.   
 
Construction of PA14 lysogens. Lysogens were obtained by first spotting phage onto a 
bacterial lawn, then streaking out surviving colonies from phage spots. These colonies were 
screened for phage resistance using a cross streak method, and lysogeny verified by prophage 
induction.  
 
Pyocyanin Repression Assay. The pyocyanin repression assay was performed as previously 
described25. Lysogens were transformed with a plasmid encoding a Type I-F crRNA targeting 
the promoter region of the gene phzM, which is required for the synthesis of the green pigment 
pyocyanin. As a control, each lysogen was also transformed with the empty vector plasmid. 
These strains were grown overnight (~16 h) in 5 mLs of LB media supplemented with 50 µg ml−1 
gentamicin and 0.01% arabinose, to induce expression of the crRNA. Pyocyanin was extracted 
with an equal volume of chloroform, and then mixed with a half-volume of 0.2 M HCl, which 
produces a pink color proportional to the amount of pyocyanin and can be quantified by 
measuring absorbance at 520 nm.  The absorbance value of each crRNA-expressing lysogen 
was expressed as a percentage of the pyocyanin level measured in the empty vector control 
lysogen. Samples were measured in technical triplicate.  
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Statistical Testing. This study used a two-tailed unpaired Student’s T-test for statistical testing.  
In all cases, sample size is n = 3, degrees of freedom is n-1, confidence interval is 95%. In all 
plots, bar or data point height is equivalent to the mean and error bars are shown as +/-
1*standard deviation (SD).  
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Figure 4.1. Characterization of kinB::Tn mutants 
 a. A streak plate on X-gal plates, showing strains involved in this study and isolated 
transposon (Tn) insertions. csy3::lacZ is a derivative of WT PA14, and is the 
unmutagenized parent of kinB::Tn 1-3.   
b. β-galactosidase measurements of strains grown in liquid culture for the indicuated 
time. Measurements for the unmutagenized (csy3::lacZ) parent strain and three isolated 
kinB transposon mutants (kinB::Tn1-3) are shown, as well as a control PA14 culture with 
no lacZ insertion. 
c. Phage titration on lawns of the kinB::Tn1 mutant transformed with empty vector or 
kinB.  
d. Spot titration of phages JBD26 (CR2_sp17, sp20-targeted, possessing acrIF4), 
JBD25 (CR1_sp1 targeted) on kinB::Tn mutants and ∆CRISPR-Cas. These experiments 
have been replicated at least 2 times with consistent results. 
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Figure 4.2: A forward genetic screen identifies a role for an alginate-activating 
pathway in repressing CRISPR-Cas immunity 
 a. Efficiency of immunity (EOI) against isogenic phages DMS3acrIE3 (non-targeted), 
DMS3macrIE3 (no I-F anti-CRISPR, CRISPR- targeted), and DMS3macrIF4 (weak I-F anti-
CRISPR, CRISPR-targeted). Plaque forming units (PFUs) are presented as a ratio 
relative to the number of PFUs measured on WT PA14, quantified on two independent 
kinB transposon mutants (kinB::Tn1 and kinB::Tn2). Tn mutants show altered EOI 
against DMS3macrIF4  relative to WT (Tn1, P = 2.9 x 10-3, Tn2, P = 3.2 x 10-3)  
b. A cartoon summarizing the KinB/AlgB two component system and downstream 
effects, based on prior work46 (see text) with CRISPR-Cas regulation added.  
c,d,e. EOI measurements for indicated ∆algB, ∆kinB, ∆algR, and ∆algU strains with 
complementation. Mutants show altered EOI against DMS3macrIF4 relative to WT (∆kinB + 
EV, P = 4.30 x 10-4 , ∆kinB + P390S, P = 5.6 x 10-6 ∆algB + EV, P = 2.8 x 10-3, ∆algB + 
D59N, P = 1.8 x 10-2 ∆algR + EV, P = 1.9 x 10-2,  ∆algU + EV, P = 6.6 x 10-3).  
 f. csy3::lacZ β-galactosidase activity over time in the indicated strain backgrounds. 
Experiment was replicated twice with fewer timepoints and consistent results seen.  All 
EOI data are represented as the mean of 3 biological replicates +/- SD and β-
galactosidase reporter activity is represented as the mean of 3 technical replicates. Two-
tailed unpaired Student’s T-test was used to calculate P values, *p < 0.05, **p < 0.01, 
***p < 0.001 
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Figure 4.3. Double knockouts of pathway members 
 a-b. Efficiency of immunity measurements for indicated mutants relative to WT. 
 a. Double knockouts show ∆kinB combined with algB, algU, algR, or amrZ. EOI 
measurements are shown as the mean of 3 biological replicates, +/- S.D. Mutants show 
increased EOI against DMS3macrIF4 relative to WT (∆kinB∆algB, P = 3.8 x 10-2, 
∆kinB∆algU, P = 5.9 x 10-3, ∆kinB∆algR , P = 1.5 x 10-2 , ∆kinB∆amrZ, P = 3.2 x 10-3)  
Two-tailed unpaired Student’s T-test was used to calculate P value, *p < 0.05, **p <0.01.  
b. Indicated knockouts were combined with csy3::lacZ, EOI shown as the mean of two 
biological replicates.. These experiments have been replicated at least 2 times with 
consistent results.  
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Figure 4.4. The KinB/AlgB pathway modulates Cas3 and Csy protein and RNA 
levels  
a. qRT-PCR measurements of transcript levels of cas3 (red) and csy3 (yellow) 
normalized to the housekeeping gene rpsL after 8 h of growth in liquid culture. 
Measurements are represented as the mean of 3 technical replicates.  
b. Measurement of the fluorescence levels of Cas3-sfCherry (red) or Csy1-sfCherry 
(yellow) reporter strains after 10 h of growth in liquid culture. Fluorescence 
measurements are represented as the mean of 3 biological replicates +/- SD. Mutants 
show altered Cas3-sfCherry levels (∆kinB, P = 7.8 x 10-3 ∆algR, P = 1.5 x 10-4  ∆algU, P 
= 1.1 x 10-4) and Csy1-sfCherry levels relative to WT (∆kinB, P = 3.3 x 10-5, ∆algR, P = 
1.5 x 10-4, ∆algU, P = 1.1 x 10-4). Two-tailed unpaired Student’s T-test was used to 
calculate P values,*p < 0.05, **p < 0.01, ***p < 0.001.  
c. Spot titration of F3 (DMS3macrIF3) or F1 (DMS3macrIF1) on dCas3 (dead Cas3) or ∆csy3 
(active Cas3, no Csy complex) strains. Phages are targeted by natural spacer CR2_sp1, 
as well as crRNAs designed to target DMS3m genome in positions designated on ORF 
map.  
d. Spot titration of DMS3macrIF3 and DMS3macrIF1 phages on WT PA14 or deletion 
mutants expressing the indicated crRNA. Plaquing experiments were replicated 3 times 
and consistent results seen.  
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Figure 4.5. AmrZ is a surface-activated repressor of CRISPR-Cas immunity  
a. Efficiency of immunity (EOI) against phages DMS3acrIE3 (non-targeted) and 
DMS3macrIF4 (CRISPR-targeted). Plaque forming units (PFUs) were quantified on ∆amrZ 
or the complemented strain, then represented as a ratio of the number of PFUs 
measured on WT PA14. ∆amrZ + EV shows increased EOI against DMS3macrIF4  relative 
to WT (P = 7.3  x 10-4). EOI measurements are represented as the mean of 3 biological 
replicates +/- SD.  
b. Growth curves of PA14 WT and ∆amrZ infected with 106 PFU of virulent DMS3macrIF4 
alongside uninfected controls. 
 c. EOI against virulent DMS3macrIF4 in liquid culture of WT and ∆amrZ strains (CRISPR 
active) or WT csy3::lacZ and ∆amrZ csy3::lacZ (CRISPR inactive). PFUs were quantified 
after 24 h from ∆amrZ or amrZ csy3::lacZ, then represented as a ratio of PFUs from WT 
or WT csy3::lacZ, respectively.  OD600 and EOI measurements are represented as the 
mean of 3 biological replicates +/- SD. ∆amrZ and ∆amrZ csy3::lacZ show no significant 
difference of EOI relative to WT and WT csy3::lacZ, respectively (∆amrZ, P = 0.6 ∆amrZ 
csy3::lacZ, P = 0.08).  
d, e. Timecourse of the fluorescence levels of Csy1-sfCherry reporter strains during 
surface-association (d) or planktonic growth (e). ∆amrZ has increased Csy1-sfCherry 
levels during surface association relative to WT (10 h, P = , 8.9 x 10-4, 15 h, P = 1.5 x 10-
3, 20 h, P = 2.0 x 10-2, 25 h, P = 2.2 x 10-4 , 30 h , P = 7.0 x 10-4)  f. Normalized 
fluorescence measurements of  WT Cas3-sfCherry (red) or Csy1-sfCherry (yellow) 
overexpressing the indicated transcription factor after 10 h growth in liquid culture. AmrZ 
and AlgU overexpression reduced Cas3-sfCherry (AmrZ, P = 1.5 x 10-3, AlgU, P = 7.8 x 
10-3 ) and Csy1-sfCherry (AmrZ, P = 7.5 x 10-6, AlgU, P = 9.9 x 10-5 ) levels relative to 
WT. Fluorescence measurements are represented as the mean of 3 biological replicates 
+/- SD. Two-tailed unpaired Student’s T-test was used to calculate P values, ns = not 
significant, *p < 0.05, **p < 0.01, ***p < 0.001.  
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Figure 4.6. AmrZ activity in liquid growth 
a. qRT-PCR measurements of transcript levels of csy3 (light grey) and cas3 (dark grey) 
normalized to the housekeeping gene rpsL after 8 h of growth in liquid culture. 
Measurements are represented as the mean of 3 technical replicates.  
b. Measurement of the fluorescence levels of Csy1-sfCherry (light grey) or Cas3-
sfCherry (dark grey) reporter strains after 10 h of growth in liquid culture. Fluorescence 
measurements are represented as the mean of 3 biological replicates +/- SD. Cas3-
sfCherry (P = 0.26) and Csy1-sfCherry levels (P = 0.35) in ∆amrZ did not differ 
significantly from WT. Two-tailed unpaired Student’s T-test was used to calculate P 
value, ns = not significant  
c. csy3::lacZ β-galactosidase activity from PA14 WT csy3::lacZ transformed with either 
empty vector (EV) or a plasmid overexpressing AmrZ (+AmrZ). β-galactosidase reporter 
activity was measured after 8 h in liquid growth and is represented as the mean of 3 
technical replicates. Experiment was replicated two times with consistent results.   
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Figure 4.7. Phage-derived AmrZ homologs control CRISPR-Cas immunity 
 a. Structure of an AmrZ tetramer bound to 18bp of operator DNA38 with DNA-contacting 
residues highlighted in red.  
b. Alignment of six mobile AmrZ homologs and the native PA14 AmrZ homolog, with the 
ribbon-helix-helix DNA binding domain schematized and DNA-contacting residues 
indicated with red arrows and text.  
c. Efficiency of immunity (EOI) against DMS3acrIE3 (non-targeted) and DMS3macrIF4 
(CRISPR-targeted). Plaque forming units (PFUs) were quantified on ∆amrZ or the 
strains complemented with AmrZ homologs, and represented as a ratio to the number of 
PFUs measured on WT PA14. Measurements are represented as the mean of 3 
biological replicates +/- SD.  
d. Normalized fluorescence levels of Csy1-sfCherry reporter strains expressing AmrZ 
homologs after 10 h of growth in liquid culture, shown as mean of 3 biological replicates, 
+/- SD. AmrZ homologs from PA14, Phi3, PaBG, and JBD68 repressed Csy1-sfCherry 
relative to WT (PA14, P = 7.5 x 10-6, Phi3, P = 1.5 x 10-5 ,PaBG, P = 1.3 x 10-5 , JBD68, 
P = 1.9 x 10-3).  
e. Efficiency of plaquing (EOP) of non-targeted DMS3acrIE3 phage (NT) or targeted 
DMS3macr phages. EOP is the ratio of PFUs on PA14 WT over PFUs formed on PA14 
∆CRISPR, represented as the mean of 3 biological replicates, +/- S.D. N.D. = not 
detectable.  
f. Fluorescence levels of dCas3::csy1-sfCherry after 16 h liquid growth lysogenized with 
the indicated DMS3macr  phage, normalized to the unlysogenized control (-),and  
represented as the mean of 3 biological replicates +/- SD. Expression of AmrZPhi3 ( P = 
4.9 x 10-4) and AmrZPaBG (P = 2.8 x 10-4) from a prophage repressed Csy1-sfCherry 
expression relative to an unlysogenized control.  
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g. Pyocyanin production from dCas3::csy1-sfCherry reporter strains lysogenized with the 
indicated DMS3macr phage or the unlysogenized control (-) after 16 h of growth in liquid 
culture. Pyocyanin levels during phzM-targeting are shown as a percentage of pyocyanin 
levels in an empty vector control, and represented as the mean of 3 technical replicates. 
Experiment was replicated three times and consistent results seen. Two-tailed unpaired 
Student’s T-test was used to calculate P values, ns = not significant, *p < 0.05, **p < 
0.01, ***p < 0.001. 
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Figure 4.8. Cas and Csy RNA and protein levels across growth conditions 
a. Log2 of Fragments Per Kilobase of transcript per Million mapped reads (FPKM) 
shown for each I-F cas gene in PA14 in the indicated growth condition43.  
b. Log2 of protein levels for each of the I-F Cas proteins in PA14 in the indicated growth 
condition44.  
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Table 4.1. Mapped insertions from transposon mutagenesis screen  
All independent transposon insertions identified and mapped by visual screening with 
increased or decreased csy3::lacZ β-galactosidase activity. β-galactosidase activity is 
expressed as a percentage of the unmutagenized parent strain, and measurements 
were taken at a single timepoint after 8 h of growth in liquid culture. The insertion 
location in the PA14 genome is shown, along with the measured level of β-galactosidase 
enzyme at the 8 hour timepoint. These measurements were not determined (N/D) for 
strains with a growth defect. 
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Table 4.2. Mobile AmrZ homologs 
AmrZ homologs listed by the genome that encodes them, the accession number, and 
the mobile genetic element type.  
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Table 4.3. AmrZ copy number analysis of two Pseudomonas aeruginosa strains 
 AmrZ copy number analysis of two different strains of Pseudomonas aeruginosa. AmrZ 
homologs listed by accession number and their genomic coordinates. Phaster46 was 
used to identify the prophages encoding mobile AmrZ copies.  
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Table 4.4. Strains and phages used in this study
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Supplementary Table 4.5. Plasmids and primers used in this study
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